


Essential Medicines List 2013



DIRECTORATE OF HEALTH SERVICES
Govt. of NCT of Delhi







Padma Shri Prof. Ranjit Roy Chaudhury

M.B.B.S., D. Phil (Oxon), FRCP (Edin), FAMS, FNA (Ind. Med.), FIMSA, D.Sc (Hon. causa) National Professor of Pharmacology (NAMS)

Adviser - Department of Health and Family Welfare, Govt. of NCTD

Former Member, BoG – MCI

Y - 85, Hauz Khas|New Delhi - 110 016 | India | Mob: +91-9810290711

Home Phone: +91-11-26856524|Fax: +91-11-26515605

E-mail: ranjitroychaudhury@gmail.com

Foreword

I am very happy that the eighth edition of the Essential Medicines List of the National Capital Territory of Delhi is truly the product of dedicated work by a large number of consultants and clinicians and other experts from Departments like the Department of Pharmacology at the medical colleges in Delhi. Experience has taught us that List of Essential Medicines is used in the way it should be used, only if there is extensive participation in its preparation which obtains the involvement of the persons using the List.

To ensure this widespread participation in preparation of this List all heads of hospitals, health centres and offices in charge of dispensaries were informed that the List of Essential Medicines is going to be prepared and that suggestions for deletion or addition of medicines to the existing List were asked for. In two months such letters were sent out three times. All 400 suggestions received were then classified into different groups and eleven sub-committees were formed to consider carefully all the suggestions. The recommendations of the different subcommittees were then placed before the Committee and the list of Essential Medicines compiled by the Committee. In keeping with the availability of new medicines and the expanding need for new medicines a total of 406 medicines have been included in the list. The list of Medicines for use at the dispensary level comprises of 152 medicines.

This meticulous planning and the holding of meetings of so many sub-committees on schedule were only possible because of the dedicated, committed and persuasive efforts of Dr. Vandana Roy, Secretary of the Committee.

The members of the Sub-committee and the members of the Committee for compiling the List worked with zeal and committment and always gave time to participate at the meetings and provide to the Committee their specialized expertise.

Finally I will like to thank Dr. N. V. Kamat for his help and guidance which made our task easier.

We are grateful to the Government of the National Capital Territory of Delhi for giving us this task of compiling the latest List of Essential Medicines for the National Capital Territory of Delhi.

Professor Ranjit Roy Chaudhury

Rangit Ry Chardhy.

Chairman, Committee for preparing the List of Essential Medicines for the National Capital Territory of Delhi

New Delhi 25th May 2013







डा० अशोक कुमार वालिया Dr. ASHOK KUMAR WALIA स्वास्थ्य एवं परिवार कल्याण, उच्च शिक्षा व प्रशिक्षण एवं तकनीकी शिक्षा, कौशल मिशन/श्रम, सिंचाई और बाढ़ नियंत्रण मंत्री MINISTER OF HEALTH & FAMILY WELFARE, HIGHER EDUCATION & TTE, SKILL MISSION/ LABOUR, IRRIGATION AND FLOOD CONTROL राष्ट्रीय राजधानी क्षेत्र दिल्ली सरकार GOVT. OF NATIONAL CAPITAL TERRITORY OF DELHI दिल्ली सचिवालय, आई॰ एस्टेट, नई दिल्ली-110002 DELHI SECRETARIAT, I.P. ESTATE, NEW DELHI-110002 (Off.): 23392103, 23392104 (Resl.) 22458989, 22518989

D.O. No. 13 432
Date 151713

MESSAGE

The concept of essential medicine is forward looking and facilitating towards attainment of equity in health care. Delhi is credited with having a comprehensive drug policy for more than two decades and this includes preparing and updating the list of Essential Medicines, the current revision being done in 2013.

I appreciate the efforts of all members of the committee who have actively participated in the revision process and hope that this updated list of Essential Medicine will immensely benefit the patients and would further improve accessibility and availability of essential medicines in public sector health facilities.

(DR. A.K. WALIA)





S.C.L. Das, IAS सचिव Secretary



स्वास्थ्य एवं परिवार कल्याण विभाग
Health & Family Welfare Department
राष्ट्रीय राजधानी क्षेत्र दिल्ली सरकार
Govt. of National Capital Territory of Delhi
दिल्ली सचिवालय, आई.पी. एस्टेट, नई दिल्ली
Delhi Secretariat, I.P. Estate, N. Delhi
E-mail: pshealth@nic.in
TEL: 23392017 FAX: 2339246

MESSAGE

In the ever-changing field of medicine, new medicines are coming in use, displacing some older ones, everyday. In order to keep pace with this and in the interest of patients, Govt. of NCT of Delhi has revised the list of essential medicines. This eighth revision of the Essential Medicine List, as it is called, is a culmination of multiple meetings with various specialties and stakeholders. I wish to place on record my deep appreciation for my colleagues involved in this extensive and consuming exercise.

Delhi, which has been a pioneer in formulating the drug policy, shall henceforth place the Essential Medicine List on its website and revise it periodically, in line with the prescribing trend and guidelines issued by various professional and regulating bodies. Delhi would thus have made a significant transition by having a Dynamic Essential Medicine List.

I heartily congratulate the CPA and wish its continued success in its endeavour in delivering public health services.

(S.C.L. Das) Secretary (H & FW)





डॉ. एन. वी. कामत निदेशक स्वास्थ्य सेवाएँ Dr. N. V. Kamat DIRECTOR HEALTH SERVICES



राष्ट्रीय राजधानी क्षेत्र, दिल्ली सरकार निदेशालय, स्वास्थ्य सेवाएँ

GOVT. OF N.C.T. OF DELHI DIRECTORATE OF HEALTH SERVICES SWASTHYA SEWA NIDESHALAYA BHAWAN F-17, Karkardooma, Delhi-110032

E-mail : dirdhs@nic.in

PHONE: 22309220, FAX: 22306396

MESSAGE

It is a privilege to be associated with this eighth revision of Essential Medicines List, done this year. The revision required multiple sittings of the core committee and subcommittees. This revision has led to the addition of ninety seven medicines in the list and the Essential Medicines List now contains 406 medicines, which shall benefit the public at large. Inclusion of newer molecules shall also enhance the prescribing horizon of our doctors.

Unlike previous revisions, when this exercise used to be done every two years, we plan to incorporate the changes and publish the EML on our website as often as possible considering the plethora of information generated, research papers published and prescription guidelines issued from various bodies. I shall appreciated feedback and inputs from institutions and doctors for further revision of the list.

I am greatly indebted to the EDL Committee headed by Prof. Ranjit Roy Chaudhary, Prof. Vandana Roy, Member Secretary and Dr. Vijoy Kumar, Addl. Director CPA, with his team for this mammoth task.

(Dr. N.V. Kamat)





Dr. Vandana Roy
MBBS, MD, PhD
Professor
Department of Pharmacology
Maulana Azad Medical College
& Associated Hospitals
New Delhi - 110002

Phone - 2323 9271 Extn 231/237 email : roy.vandana@gmail.com

PREFACE

The Government of Delhi is committed to providing essential medicines free of cost to the people that visit it's health facilities. Towards this goal, in 1994 the Government of NCT of Delhi adopted a Drug Policy based on the Essential Medicines Concept. The objectives of the Policy were that a limited list of medicines would be available at all health facilities of the State. These medicines would be procured at reasonable prices thus enabling the medicine budget to be used for a much larger number of persons than is available. The medicines would be of good quality. The implementation of the Drug Policy has improved availability of medicines and brought down the costs of medicines that were being procured.

This Essential Medicines list has been prepared by a Committee of Specialists, after wide consultations with concerned doctors. Suggestions were asked from all health facilities both hospitals and dispensaries for inclusion and deletion of medicines. This list was then circulated amongst all the members of the Committee for Selection of Essential Medicines. Subcommittees of Specialists discussed each medicine. A lengthy and detailed process of discussion was followed.

Many new medicines have been added to the existing list and some deleted. Changes in technical specifications of some preexisting medicines have been done to make them more broad based. At all times the criteria of efficacy, safety, suitability and cost of the medicine was kept in mind while taking decisions. For some medicines availability in the market was also an important criteria.

Medicines for treatment of rheumatoid disorders, blood disorders, more medicines for cancers, ophthalmic and ENT disorders, viral disorders and diabetes have been added in tune with the disease profile of the patients visiting the Delhi Government Health facilities. To answer the need for a multivitamin tablet, since no rational combination was available, individual vitamin formulations have been added in the list. All efforts have been done to avoid combinations except where no suitable alternative was available.

This list is in no way perfect. It is a balance to try to meet the basic health care requirements of patients visiting the Delhi Govt. Health facilities. Delhi has a huge migrant population and the demand on it's health system is continuously increasing. The dynamic nature of the list ensures enough scope to continuously improve it.

I take this opportunity to sincerely thank all the members of the Committee and other doctors who gave their valuable time and inputs for the preparation of the list. A special thanks to Dr. P.S. Bhandari, Dr. Kirti Singh, Dr. Dr. Gita Mehrotra, Dr. Pankaj Sharma and V. Kaviyarasan.

Vandana Roy

Member Secretary

Vandana Kon

Committee for Selection of Essential Medicines



Committee for Selection of Essential Medicines for Hospitals under Government of NCT, Delhi

Chairman 1. Professor Ranjit Roy Chaudhury Advisor to Minister, Health & Family Welfare Govt. of NCT of Delhi 2. Dr. N.V. Kamat Member **Director Health Services** Government of NCT of Delhi 3. Sh. S. B. Shashank Member Drug Controller, Government of NCT of Delhi. or his nominee Member 4. Dr. S.K. Bhattacharya Professor & Head, Department of Pharmacology, University College of Medical Sciences. Government of NCT of Delhi. 5. Member Dr. A.P. Dubev Director Professor & Head. Department of Paediatrics, Maulana Azad Medical College & Associated Hospitals, New Delhi-2. 6. Dr. B. Ghosh Member Director, Guru Nanak Eye Center New Delhi-2, Government of NCT of Delhi. 7. Dr. Vijay Kumar Garg Member Director Professor & Head, Department of Dermatology, Maulana Azad Medical College & Associated Hospitals, New Delhi-2. 8. Dr. Anju Garq Member Director Professor, Department of Radiodiagnosis. Maulana Azad Medical College & Associated Hospitals, New Delhi-2. 9. Dr. Promila Gupta Consultant Ophthalmology & Member Medical Superintendent, Deen Dayal Upadhyay Hospital, Government of NCT, Delhi. 10. Sh. P.K. Jaggi Member Asst.Drugs Controller Government of NCT, Delhi.

Dr. B.K. Jain Member 11. Director Professor & Head. Department of Surgery, University College of Medical Sciences & Guru Teg Bahadur Hospital, GNCT, Delhi. 12. Dr. P. Kar Member Director Professor, Department of Medicine, Maulana Azad Medical College & Associated Hospitals, New Delhi-2. 13. Dr. Ashok Khurana Member Medical Superintendent. GB Pant Hospital, New Delhi-2. 14. Dr. Puneeta Mahajan Member Consultant, Obstetrics & Gynaecology & Medical Superintendent, Sanjay Gandhi Memorial Hospital, GNCT, Delhi. 15. Dr. S.V. Madhu Member Professor & Head, Department of Medicine, University College of Medical Sciences & Guru Teg Bahadur Hospital, GNCT, Delhi. Dr. Lalit Maini Member 16. Professor, Department of Orthopaedics, Maulana Azad Medical College and Associated Hospitals, New Delhi-2. 17. Dr. J. C. Passev Member Director Professor, Department of ENT, Maulana Azad Medical College and Associated Hospitals, New Delhi-2. 18. Dr. Sudha Prasad Member Director Professor, Department of Obstetrics & Gynaecology, Maulana Azad Medical College & Associated Hospitals, New Delhi-2. 19. Member Dr. Rajpal Medical Superintendent, Guru Teg Bahadur Hospital, Government of NCT of Delhi. 20. Dr. Kishore Singh Member Director Professor & Head, Department of Radiotherapy, Maulana Azad Medical College & Associated Hospitals, New Delhi-2.

21. Dr. U.C. Verma Member

Director Professor & Head, Department of Anaesthesia, Maulana Azad Medical College & Associated Hospitals, New Delhi-2.

22. Dr. Mahesh Verma Member

Director, Maulana Azad Institute of Dental Sciences, New Delhi-2

23. Dr. Vijoy Kumar Member

Additional Director
Central Procurement Agency,
Directorate of Health Services, GNCT of Delhi.

24. Dr. Vandana Roy Member
Professor, Department of Pharmacology, Secretary

Maulana Azad Medical College & Associated Hospitals, New Delhi-2.



CONTENTS

THE CONCEPT OF ESSENTIAL MEDICINES
HOW TO USE THE ESSENTIAL MEDICINES LIST

ABBREVIATIONS

ESSENTIAL MEDICINES LIST FOR DISPENSARIES & HEALTH CENTRES ESSENTIAL MEDICINES LIST FOR HOSPITALS

CATEGORIES OF MEDICINES

- 1. ANAESTHETICS: GENERAL, LOCAL, PREOPERATIVE MEDICATIONS
- ANALGESICS, ANTIPYRETICS, NONSTEROIDAL ANTI-INFLAMMATORY MEDICINES, MEDICINES FOR GOUT, RHEUMATOID DISORDERS AND MIGRAINE
- 3. ANTIALLERGIC AND MEDICINES USED IN ANAPHYLAXIS
- 4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING
- 5. ANTI-EPILEPTIC MEDICINES
- 6. ANTI-INFECTIVE MEDICINES
- ANTINEOPLASTIC, IMMUNOSUPPRESSIVES AND MEDICINES USED IN PALLIATIVE CARE
- 8. ANTI-PARKINSONISM MEDICINES
- 9. MEDICINES AFFECTING BLOOD
- 10. BLOOD PRODUCTS & SUBSTITUTES
- 11. CARDIOVASCULAR MEDICINES
- 12. DENTAL PREPARATIONS
- 13. DERMATOLOGICAL MEDICINES
- 14. DIAGNOSTIC AGENTS
- 15. DISINFECTANTS & ANTISEPTICS
- 16. DIURETICS
- 17. EAR. NOSE AND THROAT MEDICINES
- 18. GASTROINTESTINAL MEDICINES
- 19. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES
- 20. IMMUNOLOGICAL AGENTS
- 21. MUSCLE / RELAXANT & CHOLINESTERASE INHIBITORS
- 22. OPHTHALMOLOGICAL /PREPARATIONS
- 23. OXYTOCICS AND ANTIOXYTOCICS
- 24. PERITONEAL DIALYSIS SOLUTIONS
- 25. PSYCOTHERAPEUTIC MEDICINES
- 26. MEDICINES ACTING ON RESPIRATORY SYSTEM
- 27. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID BASE
- 28. SOLUTIONS FOR ENTERAL & PARENTERAL NUTRITION
- 29. VITAMINES AND MINERALS

INDEX



THE CONCEPT OF ESSENTIAL MEDICINES

INTRODUCTION

Essential Medicines

Essential medicines are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety and comparative cost effectiveness. Essential medicines are intended to be available at all times in adequate amounts, in appropriate dosage forms with assured quality and adequate information and at a price the individual and community can afford.

Medicines play a major role in protecting, maintaining and restoring the health of the people. The need for medicines depends on the profile of health problems in existence within countries. Unlike other consumer products, medicines are different because the consumer usually does not choose the medicine, it is usually determined by a doctor or a pharmacist. And medicines are costly. There are many problems in the supply and use of medicines. These include poor selection of medicines, improper quantification, variable and high prices of medicines, poor quality, improper storage, irrational prescribing and improper use. These may result in substantive economic losses.

In order to take care of all the above problems, but most important to try and improve the availability of essential medicines for majority of the patients, within available economic resources, the essential medicine concept rose in the 1970s, when it was observed that people living in large parts of the world did not have access to basic medicines. Despite spending large proportions of their health budgets on medicines, Governments were unable to provide medicines for majority of their populations. There were too many medicines of dubious efficacy and quality available in the market resulting in irrational use of medicines and a waste of economic resources.

The idea that a "limited basic list of medicines" that would meet the most vital health needs of the population should be available, took ground. A limited list of essential medicines would help in rationalizing availability, affordability, and use of medicines in populations that had no access to medicines. The World Health Organization in response to this need came out with the Essential Medicine Concept in 1975 and the first list of Essential medicines was published in 1977. Subsequently this list has been revised every two years.

Criteria for the Selection of Essential Medicines*

The choice of medicines selected for inclusion in the essential medicine list, depends on many factors.

The list of medicines that is made, has to be made with regard to the existing pattern of diseases in that area. The lists can be made at the country, state, district, city, hospital level. In all these, the determining factor for medicines to be included will be first those medicines that will take care of the priority health care needs of the population living in that area or coming to the health facility.

- 1) The medicines selected should be relevant to diseases treated at different levels of health care facility
- 2) The medicines selected depend on the training and experience of the available personnel, the finanacial resources, genetic, demographic and environmental factors

- 3) Only those medicines should be selected for which sound and adequate data on efficacy and safety are available from clinical studies and for which evidence of performance in general use in a variety of medical settings has been obtained by post marketting surveillance.
- 4) Each selected medicine must be available in a form in which adequate quality including bioavailability can be assured. Its stability under the anticipated quality conditions of storage and use must be established.
- 5) Where two or more medicines appear to be similar in the above respects, the choice between them should be made on the basis of a careful evaluation of their relative efficacy, safety, quality, price and availability.
- 6) Cost of treatment: In cost comparison between medicines, the cost of the total treatment and not only the unit cost of the medicine must be considered. The cost/ benefit ratio is a major consideration in the choice of some medicines for the list.
- 7) The choice may also be influenced by comparative pharmacokinetic and pharmacodynamic properties.
- 8) Most essential medicines should be formulated as single compounds. Fixed ratio combination products are acceptable only when the dosage of each ingredient meets the requirements of a defined population group and when the combination has a proven therapeutic effect, safety or compliance.
- 9) Factors such as the availability of facilities for manufacture or store, the ease for the patient to take and for the staff to dispense must also be considered.

Structure of the list

The list of medicines should include medicines for priority health needs of the population. The medicines would be in **two categories** i) **Core** which are defined as efficacious, safe, and cost effective medicines for priority conditions ii) **Complementary** defined as medicines for priority diseases which are efficacious, safe and cost effective but not necessarily affordable or for which specialized health care facilities or services may be needed.

The list would further have to be structured depending on the **level of health care** it is for ie i) **primary** ii) **secondary** iii) **tertiary**

Some of the medicines included in the list may further be for **restricted use**. These medicines would be those for which i) extra caution must be taken while prescribing, ii) those for which more intensive monitoring is required if prescribed, iii) expensive medicines which must be only prescribed if no cheaper alternative is available and for which approval of a Senior Doctor is required before prescribing iv) Antimicrobial medicines (AMM): these must only be prescribed if there is a clear indication for their use. The use of antimicrobial medicines should be guided as far as possible with locally available antimicrobial sensitivity data. Narrow spectrum antimicrobial medicines should be prescribed first. The use of parenteral, broad spectrum medicines should be reserved for only serious infections where a narrow spectrum AMM may not suffice.

Advantages of an Essential Medicine List

A basic list of medicines identified on the basis of health needs, with the criteria of efficacy, safety, suitability and cost in mind offers the following advantages to a health care system

- 1. The list would meet the health care requirements of majority of the population.
- 2. It is easier to put systems in place for procurement and supply and monitor their performance if the list of medicines is not huge.
- Availability of basic medicines for larger populations can be better ensured.
- 4. Quality of medicines can be monitored better.
- Doctors, pharmacists and nurses can be better informed and educated about the medicines in the list
- 6. Monitoring of the system can be better done to assess for procurement, supply, storage, quality and use

Other Systems Required to Ensure Success of an Essential Medicines Programe

Just making an Essential Medicines list is not sufficient to ensure access to essential medicines for the people. Systems have to be put in place to monitor that the medicines are available and are used judiciously and rationally. For this the health system has to have the following basic structures in place

A Good Procurement, Distribution and Storage System for Medicines

Pooled procurement of medicines helps in decreasing the costs of medicines. The money saved can thus be used for procuring more medicines for the people. The distribution and storage system should be based on well organized inventory management. This will ensure a continuous supply of medicines without stockouts.

Quality Assurance System for Medicines

A system for monitoring and assuring quality of medicines that are being provided to patients must be there. A strict criteria for ensuring that only medicines of manufacturers that follow good manufacturing practices are procured must be established. This would include laboratory testing of samples of medicines in accredited laboratories.

Drugs and Therapeutics Committee

Each health facility should have a Drugs and Therapeutics Committee (DTC). This Committee should have doctors from different medical and surgical fields in the hospital, a Pharmacologist, a Microbiologist, the store incharge and a pharmacist. The Committee would have the responsibility of making the list of essential medicines for their health facility. They would make this list based on the disease profile and prevalence of patients coming to their health facility. The list of medicines made would be based on Standard treatment guidelines. The criteria of efficacy, safety, suitability and cost would be the basic criteria that the Committee members would keep while deciding which medicines to include in the list.

They would issue guidelines for use of medicines within their health facility. The DTC would also monitor the use of medicines which are being prescribed both to inpatients and outpatients.

Formulary and Standard Treatment Guidelines

A formulary, based on the esssential medicines available for ready use of health care providers must be available. Standard treatment guidleines for common clinical conditions should be there. These will help in rationalizing use of medicines and making more informed decisions on selection of medicines.

Antibiotic (Antimicrobial) Policy and Surveillance System

For effective and appropriate use of antimicrobial medicines (AMM) in the health system, the existence of a policy for use of AMM is absolutely essential. The policy would define the principles for the rational use of AMM. Guidelines on when and how to prescribe AMM should be available for the health care providers. Support to the doctors should be available in the form of antimicrobial sensitivity data. A system for monitoring the actual use of AMM should also be in place.

Health Epidemiological data

Scientific data on disease patterns, demographic profile of patients, actual use of medicines, expendituire incurred on medicines is a basic requirement to make an effective system for improving the availability and use of medicines for the patients.

Health Economics data

Provision of data on economics of health and disease will help the admininistration make better informed decisions. Specific aspects of health economics such as loss of work days due to disease and disability and ecomonics of the same, expenditure incurred on treatment, expenditure on treatment of various diseases and profiling of cost/benefit ratio of some diseases for which treatments are expensive and outcomes not good. Availability of such data will help prioritize which medicines should be included in the essential medicine list.

Continuous Education of Health Care Providers: Doctors, Nurses and Pharmacists

Continous education about medicines, standard treatment guidelines, pharmacoeconomics, and rational pharmacotherapy is essential for all health care providers. In addition increasing awareness about Good storage practices and quality assurance measures is also a must. Health care providers would include doctors, pharmacists, nurses and health administrators. Education of consumers, that is patients, about appropriate use of medicines is also required.

It is imperative that all the above structures and components be there for the success of an Essential Medicines Programme.

Vandana Roy

Member Secretary
Committee for Seclection of Essential Medicines(Govt. Of NCT of Delhi)

* World Health Organization. The selection of essential drugs. Technical report series Number 615. Geneva: WHO; 1977

How to Use the Essential Medicines list

The list of Essential Medicines represents a minimum list of medicines which are essential to fulfill the basic health care needs of majority of patients visiting the Delhi Government health facilities. The medicines have been selected based on the criteria of efficacy, safety, suitability and cost.

There are two lists 1) for the dispensaries and 2) for hospitals. The medicines included in each have been done based on the common clinical conditions / morbidity profile of patients attending these health facilities.

The medicines have been categorised based on the pharmacological class, physiological system of use or clinical indication.

The medicines written on the left side are for Outpatient use and those on the Right side are for Inpatient use only. Medicines for Outpatient use may be used for Inpatients also.

The medicines if listed in one category, is not listed again, although it may belong to more than one category of use also.

Medicines marked with an asterisk must be used with caution and are for restricted use. In addition each hospital must make it's own list of medicines that are for restricted use.

Anti infective medicines must be used judiciously. All health facilities must make a criteria for appropriate use of antimicrobials.

All pediatric formulations should be supplied with an adequate sized measuring cap, transparent with markings shown clearly on the outer side of the cap.

All batches of medicines are to be tested for quality as per provisions of Central Procurement Agency, Government of NCT of Delhi.

Any medicine not found to be of optimum quality must be reported to Central Procurement Agency, DHS.

All health facilities must monitor the use of medicines and quantify the use.

ABBREVIATIONS

Amp Ampoule

BP British Pharmacopoeia

Cap. Capsule

CFC Chlorofluoro Carbons
CR Controlled Release

DCGI Drugs Controller General of India
DPPC Dipalmitoyl Phosphatidyl Choline

I.P Indian Pharmacopoeia

ID Intra Dermal
IM Intra Muscular

Inhal. Inhaler

IV Intra Venous

MDI Metered Dose Inhaler

MR Modified Release

NFI National Formulary of India

Oint. Ointment
Soln. Solution
Susp. Suspension

Syp. Syrup

SR Sustained Release

Tab. Tablet

USP United State Pharmacopoeia

LIST OF ESSENTIAL MEDICINES FOR DISPENSARIES AND HEALTH CENTERS - 2013

Name of the Medicines/Groups Formulation Specification

1. LOCAL ANAESTHETICS

Lignocaine with Adrenaline Inj. 2% with 5mcg/ml adrenaline

2. ANALGESICS, ANTIPYRETICS, NONSTEROIDAL ANTI-INFLAMMATORY MEDICINES, AND MEDICINES FOR GOUT

Paracetamol Tab. 500 mg

Syp. 125 mg/5 ml

Inj. 150 mg/ml

Acetyl Salicylic Acid Tab. 75 mg, 100 mg, 150 mg, 325 mg

Tab. 150 mg Dispersible

Ibuprofen Tab. 200 mg, 400 mg

Susp. 100 mg/5ml

Diclofenac Sodium Tab. 50 mg, 75 mg SR, 100 mg SR

Inj. 25 mg/ml in 3ml, 75 mg/ml aqueous form, 1ml Amp.

Gel 20 gm Tube

Tramadol* Cap. 50 mg
Pentazocin Lactate* Inj. 30 mg/ml

3. ANTI ALLERGIC AND MEDICINES USED IN ANAPHYLAXIS

Chlorpeniramine maleate Tab. 4 mg

Pheniramine maleate Tab. 25 mg, 50 mg

Syp. 15 mg/5 ml Ini. 22.75 mg/ml

Syp. 5 mg/5 ml

Inj. 25 mg/ml in 1ml Amp

Cinnarizine Tab. 25 mg Levocetirizine Tab. 5 mg

Syp. 2.5 mg/5ml

Predinisolone Tab. 5 mg

Syp. 5 mg/5ml

Hydrocortisone Sodium Succinate Inj. 100 mg/ml (powder for inj)

Dexamethasone Sodium Phosphate Tab. 0.5 mg

Inj. 4 mg/ml

Adrenaline Bitartrate Inj. 1 mg/ml
Atropine sulfate Inj. 0.6 mg/ml

Promethazine Hydrochloride

^{*} For restricted use only

4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISIONING

Charcoal Tab. 500 ma

Snake Venom Antiserum (Polyvalent) Inj. Lyophilized, Liquid

5. ANTI-EPILEPTIC MEDICINES

Carbamezapine Tab. Uncoated 100 mg, 200 mg

> Syp. 100 mg/5 ml Tab. 50 mg, 100 mg

Phenytoin sodium Susp. 30 mg/5 ml

Sodium Valproate Tab. 200 mg (enteric coated)

> Syp. 200 mg/ 5 ml

Phenobarbitone Tab. 30 mg, 60 mg

20 ma/ 5 ml Svp.

6. ANTI-INFECTIVE MEDICINES*

INTESTINAL ANTHELMINTICS

Mebendazole Tab. 100 mg

> 100 mg/5 ml (powder for suspension) Susp.

Albendazole Chewable Tab. 400 mg

> 200 mg/5 ml Susp.

> > 50 mg

ANTI-FILARIAL MEDICINES

Diethyl Carbamazine Dihydrogen

Citrate

ANTI BACTERIAL MEDICINES

Benzathine penicillin Inj. 1.2, 2.4 MU/Vial (powder for Inj)

Tab.

Amoxicillin Cap. 250 mg, 500 mg

Susp. 125 mg/5 ml

Ampicillin Cap. 250 mg, 500 mg

> 125 mg/5ml (powder for suspension) Susp.

250 mg, 500 mg Cloxacillin Cap.

> 125 mg/5 ml(powder for suspension) Susp.

125 mg, 250 mg, 500 ma Cephalexin Cap.

> Syp. 125 mg/5 ml

Erythromycin (as stearate) Tab. 250 mg

> Susp. 125 mg/5 ml (powder for suspension)

Azithromycin Tab. 250 mg, 500 mg

> Susp. 100 mg/5 ml (powder for suspension)

Ciprofloxacin Tab. 250 mg, 500 mg

Norfloxacin Tab. 100 mg dispersible, 200 mg, 400 mg coated

- 2 -

400 mg+80 mg, 800 mg+160 mg Sulfamethoxazole+Trimethoprim Tab.

> 200 mg + 40 mg/5 ml Susp.

100 mg Doxycycline Cap.

^{*} For restricted use only

ANTI FUNGAL MEDICINES

Griseofulvin Tab. 125 mg, 250 mg

Fluconazole Tab./Cap. 50 mg, 150 mg, 200 mg

Susp. 50 mg/5 ml

ANTI-LEPROSY MEDICINES

Clofazimine Cap. 100 mg

Dapsone Tab. 50 mg, 100 mg

ANTI-TUBERCULOSIS MEDICINES

EthambutolTab.400 mg, 800 mgIsoniazidTab.100 mg, 300 mgIsoniazidSyr.100 mg / 5 ml

Pyrazinamide Syr. 250 mg/5 ml Rifampicin Syr. 100 mg/5 ml

Rifampicin Cap. 150 mg, 300 mg, 450 mg

Streptomycin Inj. 0.75 gm/vial

ANTI PROTOZOAL MEDICINES

Chloroquine phosphate Tab. 250 mg

Syp. 50 mg/5 ml

Sulfadoxine + Pyrimethamine Tab. 500 mg + 25 mg

Diloxanide Furoate Tab. 500 mg

Metronidazole Tab. 200 mg, 400 mg

Susp. 200 mg/5 ml

Tinidazole Tab. 300 mg, 500 mg

ANTI-VIRAL MEDICINES

Acyclovir Tab. 200 mg, 400 mg

Oral Liquid 200 mg/5 ml

Oint. 5%

7. MEDICINES AFFECTING BLOOD

ANTI-ANAEMIC MEDICINES

Ferrous Sulfate Tab. 200 mg (equivalent to 60 mg elemental iron)

Ferrus Fumarate Drops 5 mg/ml in 15 ml Bottle

Syp. 30 mg/5 ml (elemental iron equivalet to 30 mg)

Folic Acid Tab. 1 mg, 5 mg

Iron Folic Acid Tab. Ferrous Sulphate exsiccated IP 333 mg -

335 mg (equivalent. to 100 mg of elemental iron) + Folic Acid IP 0.5 mg entric coated

Iron Folic Acid Tab. Ferrous Sulphate exsiccated IP 67 mg

(equivalent. to 20 mg of elemental iron) +

Folic Acid IP 0.1 mg

^{*} For restricted use only

Iron Folic Acid Syp. Each 5 ml contains elemental iron equivalent

to 25 mg and Folic acid 500 mcg

MEDICINES AFFECTING COAGULATION

Tranexamic acid Tab. 250 mg, 500 mg

8. CARDIO VASCULAR MEDICINES

ANTI-ANGINAL MEDICINES

Metoprolol Tab. 25 mg, 50 mg,100 mg

Tab. 25 mg, 50 mg Extended release

Glyceryl Trinitrate Tab 0.5 mg. (sublingual)
Isosorbide Dinitrate Tab. 5 mg (Sublingual), 10 mg

Isosorbide Mononitrate Tab. 10 mg, 20 mg, 40 mg

ANTIHYPERTENSIVE MEDICINES

Amlodipine Tab. 5 mg

EnalaprilTab.2.5 mg, 5 mgTelmisartanTab.20 mg, 40 mgPrazosinTab.2.5 mg, 5 mg

Methyl Dopa Tab. 250 mg

MEDICINES FOR CONGESTIVE HEART FAILURE

Digoxin Tab. 0.25 mg

HYPOLIPIDEMIC MEDICINES

Atorvastatin Tab. 10 mg, 20 mg

9. DERMATOLOGICAL MEDICINES

ANTIFUNGAL MEDICINES

Clotrimazole Cream 1%

Powder 1% Vaginal pessary 100 mg

Miconazole Nitrate Cream/Gel 2%

ANTI-INFECTIVE MEDICINES

Silver Sulfadiazine Cream 1%, 20 g and 100 g

Framycetin Cream 1%, 20 g and 100 g

Povidone Iodine Soln. 5%

Oint. 5% Vaginal pessary 200 mg

SCABICIDES & PEDICULOCIDES

Permethrin Lotion 1%, 30 ml

Cream 5%, 30 gm

Benzyl Benzoate Lotion 25%, 100 ml

ANTI INFLAMMATORY & ANTI PRURITIC MEDICINES

Betamethasone propionate Cream 0.05%

Calamine lotion LP Lotion

^{*} For restricted use only

10. DISINFECTANTS AND ANTISEPTICS

Chlorhexidine Soln. 0.20%

Tincture Benzoin Co.

Ethyl Alcohol, Denatured Soln. 70% Hydrogen Peroxide Soln. 6% w/v Gention Violet Paint 0.5%, 1%

Potassium Permanganate Crystals for Soln.

11. DIURETICS

Hydrochlorothiazide Tab. 12.5 mg, 25 mg, 50 mg

Frusemide Tab. 40 mg

Frusemide Inj. 10 mg/ml in 2 ml Amp.

Amiloride Hydrochloride Tab. 5 mg Spironolactone Tab. 25 mg

12. DENTAL PREPARATIONS

Tannic acid Gum paint 10%

Choline salicylate Soln.+benzalkonium Gel (8.7% - 9% w/v) + (0.01% - 0.02%) +

Chloride Soln+lignocaine HCI IP

2% in flavoured jelly base oral gel, 30 gm/tube

Metronidazole Oral Gel 1%, 10 gm

13. EAR, NOSE & THROAT MEDICINES

Gentamicin Ear drops 0.3% w/v

Gentamicin+Betamethasone Ear drops 0.3% w/v, +0.1% w/v

Clotrimazole Ear drops 1%
Normal Saline Nasal drops 5 ml

Xylometazoline Nasal drops 0.05%, 0.1%

Wax Dissolvent Ear drops Para dichloro benzene 2%w/v +

Benzocaine 2.7% w/v + Chlorbutol 5% w/

v + turpentine oil 15% w/v

14. GASTRO INTESTINAL MEDICINES

ANTACIDS AND OTHER ANTI ULCER MEDICINES

Magnesium hydroxide +Aluminium Tab. 250 mg + 250 mg + 50 mg

Hydroxide+Activated

Dimethicone/Simethicone

Same as Above Gel 250 mg + 250 mg + 50 mg/ 5 ml

Omeprazole Cap. 20 mg
Ranitidine Tab. 150 mg

Inj. 50 mg/2 ml

ANTIEMETIC MEDICINES

Domperidone Tab. 10 mg

Susp. 1 mg/ml

Metoclopramide Tab. 10 mg

Inj. 5 mg/ml Amp.

^{*} For restricted use only

ANTI HEMORRHOIDAL MEDICINES

Beclomethasone Dipropionate Cream 0.025% + 0.1%+2.5%

+ Phenylephrine + Lignocaine

ANTI SPASMODIC MEDICINES

Dicyclomine Tab. 10 mg

lnj. 10 mg/ml

Dicyclomine+Activated Drops 10 mg+40 mg/ml

Dimethicone/Simethicone

Hyoscine Butyl Bromide Tab. 10 mg

Inj. 20 mg/ml

LAXATIVE MEDICINES

Bisacodyl Tab. 5 mg
Ispaghula Husk Powder/Granules 100 gm

MEDICINES USED IN DIARRHOEA

ORS(Oral Rehydration Salt) I.P/WHO Powder sachet Low osmolarity:245 mmol/L: Sod Chloride 2.6

g/L, Trisodium Citrate Dehydrate 2.9 g/L, Pot

Chloride 1.5 g/L, Glucose anhydrous 13.5 g/L)

15. HORMONES, ENDOCRINE MEDICINES AND CONTRACEPTIVES

Ethinyl Oestradiol + Levonorgestrel Tab. 30 mcg + 150 mcg, Pack of 21

PROGESTERONES

Norethisterone Tab. 5 mg, 10 mg

Medroxy Progesterone Acetate Tab. 2.5 mg, 5 mg, 10 mg

INSULIN & OTHER ANTIDIABETIC MEDICINES

Glimepiride Tab. 1 mg, 2 mg, 4 mg Metformin Hydrochloride Tab. 500 mg, 850 mg

THYROID AND ANTI THYROID MEDICINES

Levothyroxine Tab. 12.5 mcg, 25 mcg, 50 mcg, 87.5 mcg,

100 mcg, 125 mcg, and 150 mcg

Hand Inj. 16. IMMUNOLOGICAL AGENTS B.C.G.vaccine I.P Inj. 0.1 ml vial (

B.C.G.vaccine I.P Inj. 0.1 ml vial (10 doses plus Final overfill of 15%)

D.P.T vaccine I.P (Diphtheria, Inj. 5 ml vial (containing 10 doses plus 15% overfill)

D.T Vaccine I.P Inj. 5 ml vial (containing 10 doses plus 15%

overfill)

Measles Vaccine I.P. Inj. 2.5 ml vial ((5 doses) plus an overfill of

15%.)

MMR Vaccine(Live) I.P Inj. 2.5 ml vial ((5 doses) plus an overfill of

15%.)

Poliomyelitis Vaccine I.P Oral: 2 ml vial ((20 doses) plus 15% overfill).

(Monovalent) OPV1

- 6 -

^{*} For restricted use only

| EML for Dispensaries 2013 |
|---------------------------|
|---------------------------|

Poliomyelitis Vaccine I.P Oral: 2 ml vial ((20 doses) plus 15% overfill).

(Monovalent) OPV3

Poliomyelitis Vaccine I.P. (Bivalent) Oral: 2 ml vial ((20 doses) plus 15% overfill) Poliomyelitis Vaccine I.P. (Trivalent) Oral: 2 ml vial ((20 doses) plus 15% overfill)

Pentavalent Vaccine I.P. Inj. Liquid, 1 vial containing 10 doses

(Hib + DPT + Hepatitis B)

Hepatitis- B Vaccine I.P 5 ml vial(containing 10 paediatric doses Inj

plus 15% over fill).

Tetanus Toxoid Vaccine LP 5 ml vial(containing 10 doses plus 15% lnj.

Typhoid Vaccine I.P. 2.5 ml vial ((5 dose vial) (with 15% over Inj.

fill))

17. MUSCLE RELAXANTS

Methocarbamol Tab. 500 mg

18. OPHTHALMOLOGICAL PREPARATIONS

ANTI INFECTIVE AGENTS

Ciprofloxacin Eve drops 0.3% Ciprofloxacin Eye Oint. 0.3% Sulfacetamide 20% Eye drops Eye drops Chloramphenicol 0.50%

ANTI-INFLAMMATORY MEDICINES

Flurbiprofen Eye drops 0.03%, 5 ml

MIOTICS & ANTIGLAUCOMA MEDICINES

Timolol 0.5%, 5 ml Eye drops Pilocarpine Eve drops 1%, 2%, 5 ml

OTHERS

Lubricating Eye Drops Eve drops Preservative free Hydroxy propyl methyl

> cellulose or sodium carboxy methyl cellulose 0.3-0.5%, stabilized with

oxychloro complex 0.005-0.008%

19. OXYTOCICS AND ANTIOXYTOCICS

Isoxsuprine Tab. 10 mg Methyl Ergometrine Maleate 0.125 mg

20. PSYCHO THERAPEUTIC MEDICINES

Tab. Alprazolam 0.25 mg, 5 mg

Tab. Diazepam 5 mg

> Inj. 5 mg/ml

Imipramine Tab. 25 mg,75 mg

^{*} For restricted use only

21. MEDICINES ACTING ON RESPIRATORY SYSTEM

Etophylline+Theophylline Tab. 100 mg (77+23 mg), 150 mg, 300 mg SR

Syp. (46.5 mg + 14 mg /5ml)

Inj. 220 mg/2 ml (169.4+50.6 mg)

Salbutamol Tab. 2 mg, 4 mg

Syp. 2 mg/5 ml

Soln. 5 mg/ml Soln. for nebulizer
Aerosol 100 mcg/dose 200 doses, MDI

Soft goldtin 5000 III 50 000 III 100 000 III

Budesonide* Aerosol 100 mcg/dose 200 doses, MDI

ANTITUSSIVES

Vitamin A

Noscapine Linctus 7 mg/5 ml
Dextromethorphan Soln. 30 mg/5 ml
Bromohexine hydrochloride Syp. 4 mg/5 ml

22. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID BASE DISTURBANCES

Dextrose Inj. 5% Sodium chloride Inj. 0.9%

23. VITAMINES AND MINERALS

Cancula

| Capsule | Soft gelatin 5000 IU, 50,000 IU, 100,000 IU |
|-----------------|--|
| Oral Oily Soln. | 100,000 IU / ml |
| Tab. | 50 mg, 100 mg |
| Tab. | 5 mg |
| Tab. | 50 mg |
| Tab. | 10 mg |
| Tab. | 50 mcg, 500 mcg |
| Tab. | 100 mg, 500 mg |
| Granules | 1 gm, (60000 IU per sachet) |
| Сар. | 0.25 mcg |
| Tab. | As per schedule V of Drugs & Cosmetics Rules 1945, GOI |
| Drops | As per schedule V of Drugs & Cosmetics Rules 1945, GOI |
| lnj. | As per schedule V of Drugs & Cosmetics Rules 1945, GOI |
| Tab. | 250 mg, 500 mg (as elemental calcium) |
| Syp. | Elemental calcium 250 mg +Vit.D ₃ 125 IU/ 5 ml |
| Tab. | 10 mg Dispersible Tablet.Equivalent to 10 mg elemental Zinc |
| Tab | Equivalent to 20 mg elemental Zinc |
| Syp. | 20 mg/5 ml |
| | Oral Oily Soln. Tab. Tab. Tab. Tab. Tab. Tab. Granules Cap. Tab. Drops Inj. Tab. Syp. Tab. |

^{*} For restricted use only

ESSENTIAL MEDICINES LIST FOR HOSPITALS

1. ANAESTHETICS

All specification of Anaesthetics to be as per I.P/B.P/USP (current edition)/ approved by DCGI

GENERAL ANAESTHETICS

Sodium thiopentone Inj. 1 gm/vial, (Powder) 0.5 gm/vial Halothane Inhal. Isoflurane Inhal. Sevoflurane Inhal. Nitrous Oxide Inhal. Inhal. Oxygen Propofol Inj. 1% Fentanyl

Fentanyl Inj. 0.05 mg/ml Ketamine Hydrochloride Inj. 50 mg/ml

OTHERS

Carbon dioxide Compressed air

LOCAL ANAESTHETICS

Bupivacaine Hydrochloride Inj. 0.5%

(Heavy) with anhydrous

dextrose

Bupivacaine Hydrochloride Inj. 0.5% &

0.25%

Lignocaine Hydrochloride Inj. 5% (with

dextrose 75

mg/ml)

Lignocaine Hydrochloride

Viscous Soln. 2%

Lignocaine Hydrochloride

Jelly 2%

Lignocaine Hydrochloride

Topical Soln. 4%

Lignocaine Hydrochloride Lignocaine Hydrochloride

Oint 5% Inj. 2%

(without adrenaline)

Lignocaine Hydrochloride Inj. 2%

(without preservative)

Lignocaine with Adrenaline Inj. 2% with

Inj. 2% with adrenaline

(1:2, 00, 000)

^{*} For restricted use only

| OUT PATIENTS | EML for | r Hosr | pitals 2013 |
|--------------|---------|--------|-------------|
|--------------|---------|--------|-------------|

IN PATIENTS ONLY

Lignocaine with Adrenaline Ini. 2% with

adrenaline

(1:80, 000)

PRE-OPERATIVE MEDICATION AND SEDATION FOR SHORT TERM PROCEDURES

Promethazine Hydrochloride Syr. 5 mg/5ml Diazepam Tab. 5 mg Midazolam

Syp 2 mg/ml

Promethazine Hydrochloride Inj. 25 mg/ml Diazepam Inj. 5 mg/ml

Inj. 1 mg/ml Midazolam Triclofos sodium Syp 500 mg/5 ml Atropine Sulphate Inj. 0.6 mg/ml Glycopyrrolate Inj. 0.2 mg/ml

2. ANALGESICS, ANTIPYRETICS, NONSTEROIDAL ANTI-INFLAMMATORY MEDICINES, MEDICINES FOR GOUT, RHEUMATOID DISORDERS AND MIGRAINE

Paracetamol Tab. 500 mg Paracetamol Paracetamol Suppository

Acetylsalicylic Acid

Acetylsalicylic Acid

Ibuprofen

250 mg, 500 mg (Aqueous Form)

Tab. Plain 75 mg, 100 mg,

150 mg, 375 mg Tab. 150 mg

Dispersible

Tab.

Paracetamol Syr. 125 mg/ 5 ml Paracetamol (I.V.)

Diclofenac Sodium

Diclofenac Sodium Buprenorphine*

Pentazocin Lactate*

Morphine Sulphate*

Tramadol*

Morphine Sulphate*

Ini. 150 ma/ml Inj. 1000 mg/100 ml

Inj. 75 mg/ml

Inj. 25 mg/ml, 3ml Tab. (sublingual)

0.2 mg

Inj. 30 mg/ml Inj. 50 mg/ml

Tab. 30 mg, 60 mg

Inj. 15 mg/ml

Ibuprofen Susp. 100 mg/5 ml Diclofenac Sodium Tab. 50 mg, 75 mg

SR, 100 mg SR

200 mg, 400 mg

Diclofenac Sodium Gel 1% w/v

Diclofenac Sodium Suppository 12.5 mg,

25 mg, 50 mg

Indomethacin Cap.(Modified

Release) 75 mg

Tramadol* Cap/Tab. 50 mg,

100 mg SR

Allopurinol Tab. 100 mg

MEDICINES FOR RHEUMATOID DISORDERS

Sulfasalazine Tab. 500 mg Hydroxy Chloroquine Tab. 200 mg

Phosphate

MEDICINES FOR MIGRAINE

Dihydroergotamine Tab. 1 mg Sumatriptan Inj. 6 mg/0.5 ml

Sumatriptan Tab. 50 mg Propranolol HCI Tab. 10 mg, 20 mg, 40 mg

| 3. ANTIALLERGIC AND MEDICINES USED IN ANAPHYLAXIS | | | | | |
|--|---|--|--|--|--|
| Levocetirizine Levocetirizine Chlorpheniramine Maleate Pheniramine Maleate Pheniramine Maleate | Tab. 4 mg | Pheniramine Maleate Hydrocortisone Sodium Succinate Dexamethasone Sodium Phosphate | Inj. 22.75 mg/ml Inj.(Powder) 100 mg/ml Tab. 0.5 mg | | |
| Cinnarizine Prednisolone | Tab. 25 mg Tab. 5 mg, | Dexamethasone Sodium Phosphate | Inj. 4 mg/ml | | |
| Prednisolone | 10 mg, 20 mg, 30 mg, 40 mg Syr. 5 mg/5 ml | Adrenaline Bitartrate | lnj. 1 mg/ml | | |
| 4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING | | | | | |

| Activated Charcoal | Tab. 125 mg, 500 mg | Snake Venom Anti Serum (Polyvalent) D-Penicillamine Deferiprone | Inj. Liquid, Lyophilized Tab./Cap 250 mg Tab. 250 mg, 500 mg |
|--------------------|------------------------|---|--|
| | | Desferrioxamine | Inj.(Powder) 500 mg in vial |
| | | Methylithionium Chloride (Methylene Blue) | Inj. 10 mg/ml |
| | | N Acetyl Cysteine | Inj. 200 mg/ml |
| | | Naloxone Hydrochloride Pralidoxime Chloride (2-PAM) | Inj. 400 mcg /ml Inj. 25 mg/ml |
| | | | |

5. ANTI-EPILEPTIC MEDICINES

| Carbamazepine | Tab. 100 mg, 200 mg uncoated, 200 mg CR, 400 mg CR | Sodium Valproate Phenytoin Sodium Phenobarbitone Magnesium Sulfate | Inj. 100 mg/ ml Inj. 50 mg/ml Inj. 200 mg/ ml Inj. 500 mg/ml |
|------------------|---|--|---|
| Carbamazepine | Syp. 100 mg/5 ml | | |
| Sodium Valproate | Tab. (enteric coated) 200 mg | | |
| Sodium Valproate | Tab. CR 200 mg, CR 500 mg | | |
| Sodium Valproate | Syp. 200 mg/ 5 ml | | |
| Phenytoin Sodium | Tab. 50 mg, | | |
| | 100 mg | | |
| Phenytoin Sodium | Susp. 30 mg/5 ml | | |

^{*} For restricted use only

| OUT PATIENTS | EML for Hospitals 2013 | IN PATIENTS ONLY |
|----------------------------------|---------------------------------------|------------------|
| Phenobarbitone Phenobarbitone | Tab. 30 mg, 60 mg Syp. 20 mg / 5ml | |
| Clonazepam | Tab. 0.5 mg, 2 mg | |
| Gabapentine | Tab. 300 mg | |
| Lamotrigine | Tab./dispersible | |
| | 25 mg, 50 mg | |
| | 6. ANTI-INFECTIVE MEDICINES* | |

INTESTINAL ANTHELMINTICS

Mebendazole
Mebendazole
Mebendazole
Mebendazole
Mebendazole

Tab. 100 mg
Powder for Susp.
100 mg/5 ml
Chewable Tab.
400 mg
Albendazole
Susp. 200 mg/5 ml
Ivermectin

Tab. 3 mg, 6 mg,

12mg

ANTI- FILARIALS

Diethylcarbamazine Tab. 50 mg

Dihydrogen Citrate

ANTI-LEISHMANIASIS

| ANTI-BACTERIALS | | | |
|--------------------------------|-------------------|------------------------------|--------------------|
| Amoxycillin | Cap. 250 mg, | Crystaline Penicillin | Inj.(Powder) |
| | 500 mg | | 0.5 MU/vial |
| Amoxycillin | Susp. 125 mg/5 ml | Benzathine Penicillin | Inj.(Powder) |
| Amoxycillin + clavulanic acid* | Tab. 625 mg | | 1.2 MU/vial, |
| | (500+125 mg), | | 2.4 MU/vial |
| | 375 mg | Procaine Penicillin G. | Inj.(Powder) |
| | (250+125 mg) | | 0.4 MU/vial |
| Amoxycillin + clavulanic acid* | Powder for. | Amoxycillin-clavulanic acid* | Inj. 600 mg, 1.2 g |
| | Susp. 125 mg + | Ampicillin | Inj.(Powder) |
| | 31.2 mg/5 ml | | 500 mg/vial. |
| Ampicillin | Cap. 250 mg, | Cloxacillin | Inj. (Powder) |
| | 500 mg | | 500 mg/vial |
| Ampicillin | Powder for Suspn. | Cephalexin | Cap. 125 mg, |
| | 125 mg/5 ml | | 250 mg, 500 mg |
| Cloxacillin | Cap. 250 mg, | Cephalexin | Syp. 125 mg/ 5 ml |
| | 500 mg | Cefixime | Tab./Cap |
| Cloxacillin | Powder for Suspn. | | 200 mg, 400 mg |
| | 125 mg/ 5 ml | Cefixime | Syp 100 mg/5 ml |

Sodium Stibogluconate

Inj. 100 mg/ ml

^{*} For restricted use only

| OUT PATIENTS | EML for Hos | spitals 2013 | IN PATIENTS ONLY |
|--|--|-------------------------------|--|
| Erythromycin (as Stearate) Erythromycin (as Stearate) | Tab. 250 mg Powder for Susp 125mg/5ml | Ceftazidime* | Inj.(Powder) 250 mg, 500 mg, 1 gm |
| Azithromycin* | Tab. 250 mg, 500 mg | Ceftriaxone* | Inj.(Powder) 500 mg, 1 gm |
| Azithromycin | Powder for Susp 250 mg/5 ml | Azithromycin* Ciprofloxacin | Inj. 500 mg Infusion |
| Ciprofloxacin | Tab. 250 mg, 500 mg | Levofloxacin* | 100 mg/50 m Inj. 500 mg/100 m |
| Norfloxacin | Tab. 100 mg Dispersible, 200 mg, 400 mg coated | Gentamicin Chloramphenicol | Inj. 40 mg/ml Inj.(Powder) 1 gm/vial |
| Levofloxacin* | Tab. 500 mg | Amikacin* | Inj. 100 mg, 250 mg, |
| Nitrofurantoin | Tab. 100 mg | | 500 mg/2 ml |
| Sulfamethoxazole | Tab. 100 mg+20 mg, | Meropenem* | Inj.(Powder) |
| + Trimethoprim | 400 mg+80 mg | Discoura illia* | 500 mg, 1 gm |
| Sulfamethoxazole | and 800 mg+160 mg | • | Inj.(Powder) |
| | Oral Susp. 200 mg+ | | 2 gm, 4 gm. |
| + Trimethoprim | 40 mg in 5 ml | Teicoplanin* | Inj. |
| Trimethoprim | Tab. 100 mg, 200 mg | Vanaamuain * | 200 mg, 400 mg |
| Doxycycline | Cap. 100 mg | Vancomycin * hydrochloride | Inj.(Powder) 250 mg, 500 mg |
| ANTI-LEPROSY MEDICINE | | riyarociiloride | 250 mg, 500 mg |
| Clofazimine | Cap. 100 mg | | |
| Dapsone | Tab. 50 mg and | | |
| Dapsone | 100 mg | | |
| ANTI-TUBERCULOSIS ME | • | | |
| Ethambutol | Tab. 400 mg, | | |
| Ethambutor | 800 mg | | |
| Isoniazid | Tab. 100 mg, | | |
| | 300 mg | | |
| Isoniazid | Syr. 100mg / 5ml | | |
| Isoniazid + Vitamin B ₆ | Syr. 100 mg + 50 mg/ 5 ml | | |
| Pyrazinamide | Tab. 300 mg, 500 mg, 750 mg | | |
| Pyrazinamide | Syr. 250 mg/5 ml | | |
| Rifampicin | Syr. 100 mg/5 ml | | |
| Rifampicin | Cap. 150 mg, 300 mg, 450 mg | | |
| Streptomycin | Inj. 0.75 gm/vial | | |

^{*} For restricted use only

| OUT PATIENTS | EML for Ho | spitals 2013 | IN PATIENTS ONLY | |
|---|---|--|---|--|
| ANTI-FUNGAL | | | | |
| Fluconazole Fluconazole | Tab. 50 mg (Dispersible) Tab./Cap. | Amphotericin B | Inj. (Powder) 50 mg, 100 mg / vial | |
| | 150 mg, 200 mg, | Fluconazole | lnj. 2 mg/ml | |
| Fluconazole Griseofulvin | Susp. 50 mg / 5 ml Tab. 125 mg, | | infusion | |
| (ultra-micronised) | 250 mg | | | |
| ANTI-PROTOZOAL MEDI | CINES | | | |
| Chloroquine Phosphate Chloroquine Phosphate Sulphadoxine + Pyrimethamine Primaquine Metronidazole Tipidazola | Tab. 250 mg Syp. 50 mg/ 5 ml Tab. 500 mg + 25 mg Tab. 7.5 mg, 15 mg Tab. 200 mg, 400 mg Susp. 200 mg / 5 ml | Chloroquine Phosphate Quinine Sulphate Quinine Sulphate Artesunate* Artesunate | Inj. 64.5 mg /ml Tab. 300 mg Inj. 300 mg/ml Tab. 50 mg Inj. 60mg anhydrous artesunic acid with a separate ampoule | |
| Tinidazole | Tab. 300 mg, 500 mg | Artesunate | 5% NaHCO ₃ For Rectal use | |
| Diloxanide Furoate | Tab. 500 mg | Mefloquine Phosphate* Metronidazole | 50 mg Tab. 250 mg base Inj. 500 mg/100 ml | |
| ANTI-VIRAL MEDICINES | | | | |
| Acyclovir* | Tab. 200 mg 400 mg | Entacavir* Ribavirin* | Tab. 0.5 mg Tab. 200 mg | |
| Acyclovir | Oral Liquid 200 mg/5 ml | Tenofovir* | Tab. 300 mg | |
| Acyclovir | Oint. 5.00% | | | |
| Acyclovir | Inj. (Powder) 250 mg | | | |
| Adeofovir* | Tab. 10 mg | | | |
| NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS* | | | | |
| | | Zidovudine (ZDV or AZT) | Tab./cap 100 mg, 250 mg, 300 mg | |
| | | Zidovudine (ZDV or AZT) | Syp./ susp. 50 mg /5 ml | |
| | | Lamivudine (3TC.) | Tab. 150 mg | |
| | | Lamivudine (3TC.) | Oral Soln. 50 mg/ 5 ml | |

^{*} For restricted use only

| OUT PATIENTS | EML for Ho | spitals 2013 | IN PATIENTS ONLY |
|---------------------------|-------------------------------|----------------------|--|
| | | Stavudine | Cap. 15 mg, 30 mg, 40 mg |
| NON-NUCLEOSIDE F | REVERSE TRANSCRIPTA | ASE INHIBITORS | |
| | | Nevirapine (NVP) | Tab. 200 mg |
| | | Nevirapine (NVP) | Oral Susp. 50 mg/5 ml |
| | | Efavirenz | Tab./Cap 200 mg, 600 mg |
| PROTEASE INHIBITO |)R | | 200 mg, 000 mg |
| THOTEAGE INTIBITE | ,,,, | Indinavir (IDV) | Cap. 200 mg, 333 mg and |
| | | | 400 mg |
| | | Atazanavir Sulfate | Cap. 100 mg, 150 mg, 300 mg |
| | | Ritonavir | Tab./Cap 100 m |
| | | Ritonavir | Syp. 400 mg/5 n |
| 7. ANTI | • | SUPPRESSIVES AND ME | DICINES |
| | USED IN PAL | LIATIVE CARE | |
| Methotrexate Tamoxifen | Tab. 2.5 mg Tab. 10 mg, 20 mg | 5-Fluorouracil | Inj. 250 mg, 500 mg, 1000 m |
| Granisetron | Tab. 1 mg, 2 mg | Bleomycin | Inj. 15 units, 30 units |
| | | Cisplatin | Inj. 10 mg, 50 mg |
| | | Cyclophosphamide | Inj. 200 mg, 500 mg, 1000 mg |
| | | Cyclophosphamide | Tab. 50 mg |
| | | Cyclosporine A | Cap. 50 mg, 100 mg |
| | | Cyclosporine A | Inj. 100 mg/ml |
| | | Cytosine Arabinoside | Inj. 100 mg, |
| | | (Cytarabine) | 500 mg, 1000 mg |
| | | Daunomycin | Inj. 20 mg, 50 m |
| | | Doxorubicin | Inj. 10 mg, 50 mg, 200 mg |
| | | Etoposide | Inj. 100 mg |
| | | L- asparaginase | Lyophilized Inj. (Powder) 10, 000 KU/ vial |
| | | Leucovorin (calcium) | Tab. 5 mg, 15 m |
| | | | |

^{*} For restricted use only

| OUT PATIENTS | EML for Hospitals 2013 | IN PATIENTS ONLY |
|----------------------|-----------------------------------|---|
| | Leucovorin (calcium) | Inj. 50 mg, 100 mg, 350 mg/vial |
| | Melphalan | Tab. 2 mg, 5 mg |
| | Mercaptopurine | Tab. 50 mg |
| | Methotrexate | Inj. 50 mg/vial |
| | Paclitaxel | Inj. 30 mg, 100 mg, 260mg /vial |
| | Procarbazine | Cap. 50 mg |
| | Vincristine | Inj. 1 mg, 2 mg / vial |
| | Carboplatin | Inj. 150 mg, 450 mg |
| | Dacarbazine | Inj. 100 mg, 200 mg, 500 mg |
| | Gemcitabine | Inj. 200 mg, 1.0 gm |
| | Oxaliplatin | Inj. 50 mg, 100 mg |
| | Vinblastine | Inj. 10 mg |
| | Imatinib | Tab. 100 mg, 400 mg |
| | Actinomycin - D | Inj. 500 mcg |
| | Ifosfamide with mesna | a Inj. 1 gm, 2 gm (1 gm + 200 mg X 3) (2 gm + 400 mg X 3) |
| | Letrozole | Tab. 2.5 mg |
| | Temozolamide | Tab. 20 mg, 100 mg, 250 mg |
| | Vinorelbine | Inj. 50 mg |
| | Zoledronic Acid | Inj. 4 mg |
| | Capecitabine | Tab. 500 mg |
| | Granulocyte Colony | Inj. 300 mcg/vial |
| | Stimulating Factor (CO Filgrastim | GSF) |
| | Granisetron | Inj. 1 mg/ml |
| | 8. ANTI-PARKINSONISM MEDICINES | |
| Levodopa + Carbidopa | Tab. 100 mg + 10 mg, 100 mg + | |

10 mg, 100 mg +

25 mg and

250 mg + 25 mg

Bromocriptine Tab. 2.5 mg Trihexyphenidyl Tab. 2 mg

^{*} For restricted use only

9. MEDICINES AFFECTING BLOOD

ANTIANAEMIC MEDICINES

| ANTIANAEMIC MEDICINES | | | |
|-----------------------|---|-------------|---|
| Ferrous Sulphate | Tab. 200 mg (equivalent to 60 mg | dextran | Inj. 50 mg elemental iron Inj. 20 mg/ml |
| | elemental iron) | 040.000 | |
| Ferrous fumarate | Drops 5 mg/ml | | |
| Ferrous fumarate | Syp 30 mg/5ml | | |
| | (elemental iron | | |
| | equivalent to 30 mg) | | |
| Folic Acid | Tab. 1 mg, 5 mg | | |
| Iron Folic Acid | Tab. Ferrous | | |
| | Sulphate | | |
| | exsiccated IP 333-335 mg | | |
| | (equiv. to 100 mg | | |
| | of elemental iron) | | |
| | + folic acid IP | | |
| | 0.5 mg | | |
| Iron Folic Acid | enteric coated Tab. Ferrous | | |
| non rono riola | Sulphate | | |
| | exsiccated IP | | |
| | 67 mg (equiv. to | | |
| | 20 mg of elemental iron) | | |
| | + folic acid IP | | |
| | 0.1 mg | | |
| Iron Folic Acid | Syp Each 5ml | | |
| | contain elemental | | |
| | | | |
| | • | | |
| | iron equivalent to 25 mg and Folic acid 500 mcg | | |

OTHERS

| | | Erythropoetin | Inj. 2000 IU, 4000 IU |
|-------------------|------------------------|---------------|--|
| MEDICINES AFFECTI | NG COAGULATION | | |
| Tranexamic acid | Tab. 250 mg, 500 mg | Enoxaparin | Inj. 40 mg/0.4 ml Prefilled Syringe |
| | | Enoxaparin | Inj. 60 mg/0.6 ml Prefilled Syringe |
| | | Enoxaparin | Inj. 20 mg/0.2 ml Prefilled Syringe |

^{*} For restricted use only

| OUT PATIENTS | EML for Ho | ospitals 2013 | IN PATIENTS ONLY |
|--|---|---|--|
| | | Heparin sodium | Inj. 1000 IU, 5000 IU/ml |
| | | Protamine Sulphate Streptokinase | Inj. 10 mg/ml Inj. 15,00,000 IU/vial |
| | | Warfarin sodium Tranexamic acid Vitamin K | Tab. 5 mg Inj. 500 mg/5 ml Inj. 10 mg/ml |
| 1 | 0. BLOOD PRODU | CTS & SUBSTITUTES | |
| | | Dextran 40 | Inj. Dextran 40, 10% w/v in Dextrose (5% w/v) |
| | | Dextran 40 | Inj. Dextran 40, 10% w/v in Nacl (0.9% w/v) |
| DI ACMA EDACTIONE | | Heta Starch (Hydroxy ethyl starch) | Inj. 6% |
| PLASMA FRACTIONS | | Factor VIII concentrate Factor IX complex (Coagulation Factors II,VII,IX,X) | Inj. 250 IU Inj. 600 IU |
| | | Human Normal Serum Albumin Human Normal Serum Albumin | Infusion 5.00% Infusion 20.00% |
| | 11. CARDIOVASO | CULAR MEDICINES | |
| ANTIANGINAL MEDICINE | S | | |
| Glyceryl Trinitrate Glyceryl Trinitrate Isosorbide dinitrate | Tab. 0.5 mg Oint. 2% Tab. 5 mg sublingual, 10 mg, 20mg | Glyceryl Trinitrate Metoprolol | Inj. 5mg/ml Inj. 1mg/ml |
| Isosorbide mononitrate | Tab. 10 mg, 20 mg, 40 mg | | |
| Metoprolol | Tab. 25 mg, 50 mg, 100 mg, and Extended Release 25 mg, | | |

^{*} For restricted use only

| OUT PATIENTS | EML for Ho | spitals 2013 | IN PATIENTS ONLY |
|-------------------------|---------------------------|-----------------------|-------------------|
| | Extended Release 50 mg | | |
| ANTIARRHYTHMIC | J | | |
| Verapamil | Tab. 40 mg, 80 mg | Verapamil | Inj. 5 mg/5 ml |
| Diltiazem | Tab. 30 mg, 60 mg, | - | Inj. 25 mg/vial |
| | 120 mg (SR) | Adenosine | Inj. 3 mg/ ml |
| Amiodarone | Tab. 200 mg | Amiodarone | Inj. 150 mg/ Vial |
| | | Lignocaine | Inj. 2% |
| | | (preservative free) | (21.3 mg/ml) |
| ANTI HYPERTENSIVE MED | DICINES | | |
| Amlodipine | Tab. 5 mg, 10 mg | Labetolol | Inj. 20 mg/ml |
| Enalapril | Tab. 2.5 mg, | Sodium Nitroprusside | Inj. 50 mg/ 5 ml |
| | 5 mg, 10mg | | |
| Telmisartan | Tab. 20 mg, 40 mg | | |
| Prazocin | Tab. 2.5 mg, 5 mg | | |
| Methyldopa | Tab. 250 mg | | |
| Labetolol | Tab. 100 mg, | | |
| Ole at the co | 200 mg | | |
| Clonidine | Tab. 0.1 mg, | | |
| CARDIAC GLYCOSIDES | 0.2 mg | | |
| | Tab 0.05 mg | Digavin | lni OEO mag/ml |
| Digoxin | Tab. 0.25 mg | Digoxin | Inj. 250 mcg/ml |
| Digoxin | Syp. 0.05 mg/ml | | |
| HYPOLIPIDAEMIC AGENTS | | | |
| Atorvastatin | Tab. 10 mg, 20 mg | g | |
| Fenofibrate | Cap. 200 mg | | |
| MEDICINES USED IN VASO | CULAR SHOCK AN | D PERIPHERAL VASCULAR | |
| | | Dobutamine | Inj. 50 mg/ml |
| | | Dopamine | Inj. 40 mg/ml |
| | | Noradrenaline | Inj. 1 mg/ml |
| | 12. DENTAL P | REPARATIONS | |
| Choline Salicylate + | Oral Gel. (8.7 to | | |
| Benzalkonium chloride + | 9% w/v),+(0.01 | | |
| Lignocaine HCI | to 0.02%) + | | |
| | 2% w/w in | | |
| | flavoured jelly | | |
| | base | | |
| Metronidazole | Oral gel 1% | | |
| Povidone Iodine | Mouth Wash 1% | | |
| Tannic Acid | Gum Paint 10% | | |

^{*} For restricted use only

13. DERMATOLOGICAL MEDICINES

ANTIFUNGAL MEDICINES

Clotrimazole Cream 1% Clotrimazole Powder 1%

(in a starch base)

Clotrimazole Vaginal Pessary

100 mg

Cream/Gel 2% Miconazole Nitrate

ANTI - INFECTIVE MEDICINES

Framycetin Cream 1% Povidone iodine Sol. 5% Povidone iodine Oint. 5% Silver sulfadiazine Cream 1%

SCABICIDES AND PEDICULOCIDES

Benzyl Benzoate Lotion 25% Permethrin Cream 5% Permethrin Lotion 1%

ANTI-INFLAMMATORY & ANTIPRURITIC MEDICINES

Betamethasone Propionate Cream 0.05% Clobetasol propionate Cream 0.05%

Calamine Lotion I.P. Lotion

KERATOPLASTIC AND KERATOLYTIC AGENTS

Salicylic acid Oint. 3%, 6%, 12% Coal tar Soln. 1% - 5%,

10% - 20%

Paint 20% Podophyllin

ULTRAVIOLET BLOCKING AGENTS

Trimethyl Psoralen Tab. 5 mg, 25 mg

OTHERS

Levamisole Tab. 50 mg, Triamcinolone acetate Inj. 10 mg, 40 mg / ml

150 mg

Levamisole Syp 50 mg/5 ml Liquid Paraffin Liquid Light Gel. 0.1% Adapalene

14. DIAGNOSTIC AGENTS

ORAL CONTRAST AGENTS

Barium Sulphate Susp. 95% w/v Barium Sulphate Powder (HD) 95% w/w

^{*} For restricted use only

| OUT PATIENTS | EML for Hospitals 2013 | IN PATIENTS ONLY |
|--------------|------------------------|------------------|
|--------------|------------------------|------------------|

Barium Sulphate Susp. 250% w/v
Barium Sulphate Powder 95%w/v

IONIC INTRA VASCULAR CONTRAST AGENTS

Sodium Diatrizoate + Inj. 60%

Meglumine Diatrizoate

Sodium Diatrizoate + Inj. 76%

Meglumine Diatrizoate

NON-IONIC INTRA VASCULAR CONTRAST AGENTS

Iohexol / Iopamidol /Inj. 250 mg/ml,Iomeprol / Ioversol /300 mg/ml,Iodixanol / Iobitridol350 mg/ml,370mg/ml,

400 mg/ml

MAGNETIC RESONANCE CONTRAST AGENTS

Gadoteric acid / Gadobenic Inj. 0.5 mmol/ml

acid / Gadodiamide /

Gadopentetate dimeglumine

15. DISINFECTANTS & ANTISEPTICS

Gentian violet Paint 0.5%, 1% Formaldehyde Tab. 1gm Chlorhexidine Soln. 0. 2% Formaldehyde Soln. 37-41% Chlorhexidine Scrub. Glutaraldehyde Activated Soln. 2% w/v

Ethyl alcohol 70% without Foaming to remain

(Denatured) Alkaline for 2 weeks

Eusol (Chlorinated lime+ Liquid

Boric acid) 1.25%+1.25% Hydrogen Peroxide Soln. 6% w/v Potassium Permanganate Crystal for Soln.

Tincture Benzoin Co. Tincture

16. DIURETICS

Glycerol Syr. Pure Mannitol Inj. 20%

Hydrochlorothiazide Tab. 12.5 mg, Frusemide Inj. 10 mg / ml

25 mg, 50 mg

Frusemide Tab. 40 mg
Amiloride Hydrochloride Tab. 5 mg

Spironolactone Tab. 25 mg, 100 mg

17. EAR, NOSE AND THROAT MEDICINES

Xylometazoline Nasal Drops 0.05%, 0.10%

^{*} For restricted use only

| OUT PATIENTS | EML for Hospitals 2013 | IN PATIENTS ONLY |
|--------------|------------------------|------------------|
| | | |

Sodium Chloride Nasal Drops 0.9%

Wax dissolvent Ear drops

> Para dichloro benzene 2% w/v + Benzocaine 2.7% w/v + Chlorbutol 5% w/v+turpentine oil 15%w/v

Choloramphenicol Ear drops 5% Ciprofloxacin Ear drops 0.5% Gentamicin Ear Drops

0.3% w/v

Clotrimazole Ear Drops 1% Betamethasone Ear drops 0.25%

Gentamicin + Betamethasone Ear Drops

0.3% w/v + 0.1%

Boric Acid Powder

Povidone Iodine **Gargle 1.00%**

Bismuth Iodoform Parrafin Paste Sol. 0.15% Icthymol Silver nitrate Crystals

Turpentine oil

18. GASTROINTESTINAL MEDICINES

ANTACIDS & OTHER ANTI-ULCER MEDICINES

Tab. 250 mg Magnesium hydroxide + Pantoprazole Inj. 40 mg aluminium hydroxide + + 250 mg Ranitidine Inj. 50 mg/2 ml + 50 mg

activated dimethicone/

simethicone

Magnesium hydroxide + Gel. 250 mg + aluminium hydroxide + 250 mg + activated dimethicone/ 50 mg/ 5 ml

simethicone

Omeprazole Cap. 20 mg Ranitidine Tab. 150 mg

PROKINETIC AGENT

Mosapride citrate dehydrate Tab. 5 mg

ANTIEMETIC MEDICINES

Metoclopramide Domperidone Tab. 10 mg Inj. 5 mg/ml Susp. 1 mg/ml Ondansetron Inj. 2 mg/ml Domperidone

Metoclopramide Tab. 10 mg Ondansetron Tab. 4 mg, 8 mg Ondansetron Syp 2 mg/5 ml

^{*} For restricted use only

ANTI- HAEMORRHOIDAL MEDICINES

Beclomethasone Cream

Dipropionate + (0.025 % + 0.1%

Phenylepherine+Lignocaine + 2.5%)

ANTI-INFLAMMATORY MEDICINES

5-Amino Salicylic Acid Tab. 400 mg

ANTI-SPASMODIC MEDICINES

Dicyclomine Tab. 10 mg Dicyclomine Inj. 10 mg/ml Dicyclomine+Activated Drops 10 mg Hyoscine Butyl Bromide Inj. 20 mg/ml

Dimethicone/ Simethicone + 40 mg /ml Hyoscine Butyl Bromide Tab. I0 mg

LAXATIVE MEDICINES

Bisacodyl Tab. 5 mg Glycerine enema Enema 20 ml

Isphagula husk Powder/Granules

100 gm

Lactulose Syp. 667 mg/ml

MEDICINES USED IN DIARRHOEA

ORS (Low osmolarity: Powder

245 mmol/L: Sod Chloride As per I.P/WHO 2.6 g/L Trisodium citrate Specification

dehydrate 2.9g/L, Pot. Chloride 1.5g/L, Glucose anhydrous 13.5g/L)

OTHERS

Urodeoxy cholic acid Tab./Cap

150 mg, 300 mg

19. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES

PITUITARY HORMONES

Octreotide Inj. 30 mcg/ml,

50 mcg/ml, 100 mcg/ml, 250 mcg/ml, 500 mcg/ml

ADRENAL HORMONES & SYNTHETIC SUBSTITUTES

Methylprednisolone Inj. 40 mg/ ml,

125 mg/ Vial, 500 mg/ Vial (all with diluent or separate diluent)

^{*} For restricted use only

CONTRACEPTIVES

Ethinyl Oestradiol + Tab. 30 mcg + Levonorgestrel 150 mcg
Ethinyl Oestradiol + Tab. 30 mcg + Levonorgestrel (extended) 150 mcg

OESTROGENS

Conjugated equine oestrogen Tab. 0.625 mg

1.25 mg

Ethinyl Oestradiol Tab. 0.05 mg

Ethinyl Oestradiol Valerate Tab. 1 mg, 2 mg

Tab. 25 mg,

50 mg, 100 mg

PROGESTERONES

Clomiphene citrate

Norethisterone Tab. 5 mg, 10 mg Tab. 100 mg, Progesterone micronized 200 mg, 400 mg Medroxy Progesterone Tab. 2.5 mg, 5 mg, 10 mg Acetate Hydroxy progesterone Inj. 250 mg, acetate(Depot) 500mg Danazol Tab. 50 mg, 100 mg, 200 mg

INSULIN & OTHER ANTIDIABETIC MEDICINES

| Metformin hydrochloride | 1ab. 500 mg, | Insulin Soluble (Human) | Inj. 40 IU/mi |
|---------------------------|----------------------|--------------------------|-----------------|
| | 850 mg | Insulin NPH (Human) | Inj. 40 IU/ml |
| Glimepiride | Tab. 1 mg, 2 mg, | Insulin Premixed (Human) | Inj. 30 % / 70% |
| | 4 mg | | in 40 IU/ml |
| Sitagliptin/Vildagliptin/ | Tab. | Insulin Premixed (Human) | Inj. 30 % / 70% |
| Saxagliptin | Sitagliptin 100 mg/ | | in 100 IU/ml |
| | Vildagliptin 100 mg/ | Insulin Glargine(Human) | Inj. 100 IU/ml |
| | Saxagliptin 5 mg | Insulin Lispro / Apart / | Inj. 100 IU |
| | | Glulisine | |

MEDICINES AFFECTING CALCIFICATION & BONE TURNOVER

Alendronate Tab. 10 mg,

35 mg, 70 mg

THYROID HORMONES & ANTITHYROID MEDICINES

Levothyroxine Tab. 12.5 mcg,

25 mcg, 50 mcg, 87.5 mcg, 100 mcg, 125 mcg, 150 mcg.

^{*} For restricted use only

| OUT PATIENTS | EML for Hospitals 2013 | IN PATIENTS ONLY |
|----------------|---|------------------|
| | Tab. 5 mg, 10 mg, 20 mg | |
| Lugol's lodine | Tab. 50 mg , Soln. 130 mg lodine/ml | |

20. IMMUNOLOGICAL AGENTS

Specifications of all immunological agents as per I.P. (current edition)

| opecifications of | an ininitianological | agents as per i.r. (current | eartion) |
|-----------------------------|----------------------|-----------------------------|---------------------|
| B.C.G.vaccine I.P | Inj. I.P | Hepatitis B Immunoglobulin | Inj. 100 IU, 200 IU |
| D.P.T vaccine I.P | Inj. I.P | Human Normal | Inj. 5% (2.5 gm in |
| (Diphtheria, Pertussis and | | Immunoglobulin (IV-Ig) | 50 ml, 5 g in |
| Tetanus toxoids) | | | 100 ml) |
| D.T Vaccine I.P | Inj. I.P | Anti tetanus | Inj. 250 IU/ml, |
| Measles Vaccine I.P. | Inj. I.P | Immunoglobulin | 500 IU/ml, |
| MMR Vaccine(Live) I.P | Inj. I.P | | 1000 IU/ml |
| Poliomyelitis Vaccine I.P | Oral: I.P | Anti Diptheritic Serum | Inj. 10000 IU/Amp |
| (Monovalent) OPV1 | | | 20000 IU/Amp |
| Poliomyelitis Vaccine I.P | Oral: I.P | Anti Rh (D) Immunoglobulin | Inj. 300 mcg |
| (Monovalent) OPV3 | | | |
| Poliomyelitis Vaccine I. P. | Oral: I.P | | |
| (Bivalent), | | | |
| Poliomyelitis Vaccine I. P. | Oral: I.P | | |
| (Trivalent) | | | |
| Pentavalent Vaccine | Inj. I.P | | |
| (Hib + DPT + Hepatitis B) | | | |
| Hepatitis- B Vaccine I.P | Inj. I.P | | |
| Anti Rabies Vaccine I.P | Inj.:IM/ID | | |
| (Chick embryo/ Vero cell/ | I.P | | |
| Human diploid) | | | |
| Tetanus Toxoid Vaccine I.P | Inj. I.P | | |
| Typhoid Vaccine I.P | Inj. I.P | | |
| Rabies Immunoglobulin | Inj. 150 IU/ml | | |
| | (Human) / | | |

300 IU/ml (Equine) 21. MUSCLE RELAXANT & CHOLINESTERASE INHIBITORS

| Methocarbamol | Tab. 500 mg | Atracurium Besylate | Inj. 10 mg/ml |
|---------------|-------------|---------------------|----------------|
| Neostigmine | Tab. 15 mg | Rocuronium | Inj. 50 mg/ml |
| | | Vecuronium | Inj. (Powder) |
| | | | 2 mg/ml amp. |
| | | Succinyl choline | Inj. 50 mg/ml |
| | | Neostigmine | Inj. 0.5 mg/ml |

^{*} For restricted use only

22. OPHTHALMOLOGICAL /PREPARATIONS

ANTI-ALLERGIC MEDICINES

Naphazoline HCl + Eye Drops
Chlorpheniramine + Naphazoline
Zinc Sulfate hydrochloride

0.05- 0.1% +

Chlorpheniramine

maleate
0.01- 0.1% +
Zinc sulphate
0.12 - 0.15 % +
Benzylalkonium
chloride as
preservative-till
0.12 % Optional

addition of Menthol/ Camphor -

0.0025 - 0.005 %

Olapatadine * Eye Drops 0.10%

ANTI-INFECTIVE AGENTS

Ciprofloxacin Eye Drops 0.30%
Ciprofloxacin Eye Oint 0.30%
Sulfacetamide Eye drops 20%
Chloramphenicol Eye Drops

0.5%, 1%

Gentamycin Eye Drops 0.30%
Tobramycin Eye Drops 0.30%
Natamycin Eye Drops 5%
Acyclovir Eye Oint 3%

ANTI-INFLAMMATORY AGENTS

Flurbiprofen Eye Drops 0.03% Dexamethasone Eye Drops 0. 1%

Dexamethasone+Gentamycin Eye Drops

0.1%+ 0.3%

Dexamethasone+Ofloxacin Eye Drops

0.1%+ 0.3%

^{*} For restricted use only

| OUT PATIENTS | EML for Ho | spitals 2013 | IN PATIENTS ONLY |
|--|---|---|---|
| MIOTICS & ANTIGLAUCOM | A MEDICINES | | |
| Pilocarpine | Eye Drops 1%, 2% | Pilocarpine | Inj. 0.5%/ml preservative free |
| Timolol | Eye Drops 0. 5% | | for intraocular use |
| Brimonidine | Eye Drops 0.20% | | |
| Dorzolamide | Eye Drops 2.00% | | |
| Acetazolamide | Tab. 250 mg | | |
| MYDRIATICS | | | |
| Tropicamide | Eye Drops 1% | | |
| Homatropine Hydrobromide | Eye Drops 2% | | |
| Atropine Sulphate | Eye Oint 1% | | |
| Phenylephrine | Eye Drops 10% | | |
| Tropicamide + Phenylephrine | Eye Drops (0.8% to 1%) + 5% | /o | |
| OTHERS | , | | |
| Lubricant eye drops, preservative free | methyl cellulose 0.3 -0.5% + Stabilized oxy choloro complex 0.005 - 0.008 % | Hyaluronidase Hydroxy Propyl Methyl Cellulose Fluroscein Sodium Trypan Blue | Inj. 1500 Unit/ml Inj. 2 % prefilled syringe Inj. 10% Inj. 0.10% and 0.08% |
| Sodium Chloride | Eye Drops 5% | | |
| Sodium Chloride | Eye Oint 6% | | |
| Hydroxy Propyl Methyl Cellulose | Eye Drops 0. 7% | | |
| Proparacaine | Eye Drops 0.50% | | |
| Fluroscein Sodium | Strips 1 mg, single sterile unit | | |
| 23. OXYTOCICS AND ANTIOXYTOCICS | | | |
| Mathylana matrina Malasta | Tab 0.105 | | In: []] / mal |

Methylergometrine Maleate Tab. 0.125 mg Oxytocin Inj. 5 IU/ ml Misoprostol Tab. 200 mcg, Inj. 0.2. mg/ml Methylergometrine Maleate Vaginal Tab Inj. 0.5 mg/Syringe Dinoprostone Ethacridine Lactate Inj. 1 mg/ ml 25 mcg Mifepristone Inj. 5 mg/ml Tab. 200 mg Isoxsuprine Isoxsuprine Inj. 250 mcg/ml Tab. 10 mg PGF 2 α as Nifedipine Tab. 10 mg tromethamine

^{*} For restricted use only

| OUT PATIENTS | EML for Ho | spitals 2013 | IN PATIENTS ONLY |
|----------------------------|--------------------|---|--|
| OTHERS | | | |
| | | Betamethasone | Inj. 4 mg/ml |
| 24 | . PERITONEAL DI | ALYSIS SOLUTIONS | |
| | | Intraperitoneal Dialysis Concentrate | Inj. 1.5% dextrose Inj. 2.5% dextrose Inj. 4.5% dextrose |
| 2 | 5. PSYCOTHERA | PEUTIC MEDICINES | |
| Alprazolam | Tab. 0.5 mg, | Haloperidol | Inj. 5 mg/ ml |
| | 0.25 mg | Fluphenazine Decanoate | Inj. 25 mg / ml |
| Zolpidem | Tab. 5 mg, | Lorazepam | Inj. 2 mg/ ml |
| | 6.5 mg | | |
| | Extended Release |), | |
| | 12.5 mg | | |
| | Extended Release |) | |
| Lorazepam | Tab. 1 mg, 2 mg | | |
| Trifluoperazine | Tab. 5 mg | | |
| Chlorpromazine | Tab. 25 mg, | | |
| | 50 mg, 100 mg | | |
| Haloperidol | Tab. 5 mg, 10 mg | | |
| Olanzapine | Tab. 2.5 mg, 5 mg | | |
| Risperidone | Tab. 2 mg | | |
| Amitriptyline | Tab. 10 mg, | | |
| | 25 mg, 75 mg | | |
| Imipramine | Tab. 25 mg, | | |
| | 75 mg | | |
| Clomipramine hydrochloride | Tab./Cap 25 mg | | |
| Fluoxetine | Cap. 20 mg | | |
| Lithium carbonate | Tab. 300 mg | | |
| Donepezil | Tab. 5 mg | | |
| Naltrexone | Tab. 50 mg | | |
| 26. MED | ICINES ACTING O | N RESPIRATORY SYSTEM | |
| Bromhexine Hydrochloride | Syp. 4 mg/ 5 ml | Etophylline+ Theophylline | Inj. 220 mg/2 ml |
| Noscapine | Drops 1.83 mg /ml | • • | (169.4 mg + |
| Noscapine | Linct. 7 mg / 5 ml | | 50.6 mg) |
| Dextromethorphan | Soln. 30 mg/5 ml | Salbutamol | Soln. for |

Diphenhydramine

Salbutamol

Nebulizer

5 mg/ml

Syp. 12.5 mg/ 5 ml

Tab. 2 mg, 4 mg

^{*} For restricted use only

| OUT PATIENTS | EML for Hospitals 2013 | IN PATIENTS ONLY |
|---------------------------|--|--|
| Salbutamol* | Syp. 2 mg/ 5 ml Ipratropium Bromide Inh. 100 mcg. / dose, Aerosol, | Soln. for nebulizer 250 mcg/ ml |
| Ipratropium Bromide* | MDI, CFC free Surfactant Solution for Inh. 20 mcg /dose, intratracheal instilation Aerosol, MDI CFC free | Soln. Naturally derived surfactant |
| Etophylline+ Theophylline | Tab. 100 mg (77+23mg), 150 mg SR, 300 mg SR | suspension for ultra tracheal admnistration. |
| Etophylline+ Theophylline | Syr. (46.5 + 14 mg /5ml) | Should contain surfactant |
| Budesonide* | Inh. 100 mcg./dose, Aerosol, MDI CFC free | proteins SP-B and SP-C. Should contain atleast 25 mg/ml of Phospholipid. |

27. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID BASE DISTURBANCES

| Dextrose | Inj. 5%, 10%, 25%, 50% |
|--|---|
| Sodium Chloride Dextrose with Saline (DNS) Dextrose with Saline (N/2 DNS) Dextrose with Saline | Inj. 0.9% Inj. 5% + 0.9% Inj. 5% + 0.45% Inj. 5% + 0.22% |
| (N/4 DNS) Dextrose with Multiple electrolytes | Inj. pH:4-6, calories:170- 180 per litre. calculated osmolarity: 340-380 mOsm/l, Dextrose 5% with Sodium 23-25 mEq/L, Choloride 24-29 mEq/ |

^{*} For restricted use only

| OUT PATIENTS | EML for Hospitals 2013 | IN PATIENTS ONLY |
|--------------|--------------------------------|----------------------|
| | | L, Lactate |
| | | 23 mEq/L, |
| | | Potassium |
| | | 20 mEq/L, |
| | | Magnesium |
| | | 3 mEq/L, |
| | | Phosphate |
| | | 3 mEq/L |
| | Ringer Lactate | lnj. |
| | Potassium Chloride | Inj. 150 mg/ml |
| | Sodium Bicarbonate | Inj. 7.5% |
| | | Isotonic |
| | Calcium Gluconate | Inj. 10% |
| | Glycine | Inj. 1.5% |
| | Water for Injection | Inj. 2 ml, |
| | | 5 ml, 10 ml |
| | Distilled water | Inj. |
| 28. SOLUTION | S FOR ENTERAL & PARENTERAL NUT | RITION |
| | Enteral nutrition | Powder / Granules |

| Protein 12-15%, |
|-----------------|
| Fat 30-40%, |
| Carbohydrate |
| 60%, with |
| Recommended |
| daily intake of |

all minerals & vitamines, > 1500 kcal/d; 270-1100 mOsm /kg(H₂0)

PARENTERAL NUTRITION

Amino acid 5% solution Infusion

All essential and non

essential amino acid. 450-800 mOsmol/l

Amino acid 10% solution Infusion

All essential

^{*} For restricted use only

| OUT PATIENTS | EML for Ho | espitals 2013 | IN PATIENTS ONLY |
|---|---|---|--|
| LIPID EMULSION | | | and non essential amino acid. 1000- 1200 mOsmol/l |
| LIPID EWOLSION | | Lipid emulsion (peripheral)* | Infusion 10%, 250-350 mOsmol/l |
| | | Lipid emulsion (central)* | Infusion 20%, 250-350 mOsmol/I |
| TOTAL PARENTERAL NUTF | RITION (TPN) | Mixed TPN (peripheral)* | Infusion Amino acid + Electrolytes + Lipids + Dextrose, 700- 800 mOsmol/l |
| | | Mixed TPN (central)* | Infusion Amino acid + Electrolytes + Lipids + Dextrose, 1000-2000 mOsmol/I |
| | 29. VITAMINS | AND MINERALS | |
| Vitamin A (Retinol) as palmitate | Cap 5000 IU, 50000 IU, 100000 IU, 200000 IU | Vitamin A (Retinol) as palmitate Vitamin B ₁ (Thiamine | Inj. (water miscible 1 Lac IU in 2ml Amp. Inj. 100 mg/ml |
| Vitamin A (Retinol) as palmitate | Oral Oily Soln. 100000 IU/ml in multi dose dispenser | pyrophosphate) Vitamin B_{12} Vitamin D_3 (cholecalciferol) Vitamin K | Inj. 500 mcg/ml Inj. 6 lac IU/ ml Inj. 1mg/ 0.5 ml |
| Vitamin B ₁ (Thiamine) | Tab. 50 mg, 100 mg | Vitamin K Multivitamin | Inj. 10 mg/ml Inj. As per |
| Vitamin B ₂ (Riboflavin) Vitamin B ₃ (Nicotinamide) Vitamin B ₆ (Pyridoxine) | Tab. 5 mg Tab. 50 mg Tab. 10 mg | | schedule V of Drugs & Cosmetics |

^{*} For restricted use only

| OUT PATIENTS | EML for Hospitals 2013 | IN PATIENTS ONLY |
|--|------------------------------------|------------------|
| Vitamin B ₁₂ | Tab. 50 mcg, | Rules 1945, |
| (Cyanocobalamin) | 500 mcg | GOI |
| Vitamin C | Tab. 100 mg, Calcium Gluconate | Inj. 100 mg/ml |
| | 500 mg | in 10 ml Amp. |
| Vitamin D ₃ (cholecalciferol) | Granules (60000 IU | |
| | per sachet) | |
| Albhacalcidal | Cap. 0.25 mg | |
| Multivitamin | Tab. As per | |
| | schedule V of | |
| | Drugs & Cosmetics | |
| | Rules 1945, GOI | |
| Multivitamin | Drops As per | |
| | schedule V of | |
| | Drugs & Cosmetics | |
| | Rules 1945, GOI | |
| Calcium carbonate | Tab. 250 mg, | |
| | 500 mg (as | |
| | elemental calcium) | |
| Calcium carbonate + | Syp. Elemental | |
| Vitamin D ₃ | calcium 250 mg + | |
| 7: 0:-16-4- | Vit. D ₃ 125 IU/5 ml | |
| Zinc Sulfate | Tab. 10mg | |
| | Dispersible Tab. | |
| | Equivalent to 10 mg elemental Zinc | |
| Zinc Sulfate | | |
| Zinc Sunate | Tab. Equivalent | |
| | to 20 mg elemental Zinc | |
| Zinc Sulfate | Syrup 20 mg/5 ml | |
| Zinc Juliate | Syrup 20 mg/3 mi | |

| INDEX | | | | | | | |
|-------|--|----------|-------|--|----------|--|--|
| S.No. | Drug Name | Page no. | S.No. | Drug Name | Page no. | | |
| 1 | 5-Amino Salicylic Acid | 23 | 30 | Anti Snake venom (Polyvalent) | 2, 11 | | |
| 2 | 5-Fluorouracil | 15 | 31 | Artesunate | 14 | | |
| 3 | Acetazolamide | 27 | 32 | Atazanavir Sulfate | 15 | | |
| 4 | Acetylsalicylic Acid | 1, 10 | 33 | Atorvastatin | 4, 19 | | |
| 5 | Actinomycin-D | 16 | 34 | Atracurium | 25 | | |
| 6 | Activated Charcoal | 11 | 35 | Atropine Sulphate | 1, 10,27 | | |
| 7 | Acyclovir | 3,14,26 | 36 | Azithromycin | 2, 13 | | |
| 8 | Adapalene | 20 | 37 | B.C.G. IP (freez dried bacillus | | | |
| 9 | Adenosine | 19 | | Calmette Guerin) with a suitable diluent. The label on each vial | | | |
| 10 | Adeofovir | 14 | | should include Vaccine Vial Monitor (VVM) designed to | | | |
| 11 | Adrenaline Bitartrate | 1, 11 | | meet the heat stability curve | | | |
| 12 | Albendazole | 2, 12 | | of the vaccine supplied | 6, 25 | | |
| 13 | Alendronate | 24 | 38 | Barium Sulphate | 20,21 | | |
| 14 | Allopurinol | 10 | 39 | Beclomethasone Dipropionate + Phenylepherine | + | | |
| 15 | Alphacalcidol | 8,32 | | Lignocaine | 6,23 | | |
| 16 | Alprazolam | 7, 28 | 40 | Benzathine Penicillin | 2, 12 | | |
| 17 | Amikacin | 13 | 41 | Benzyl Benzoate | 4,20 | | |
| 18 | Amiloride Hydrochloride | 5, 21 | 42 | Betamethasone | 22,28 | | |
| 19 | Amino acid solution | 30 | 43 | Betamethasone propionate | 4, 20 | | |
| 20 | Amiodarone | 19 | 44 | Bisacodyl | 6, 23 | | |
| 21 | Amitriptyline | 28 | 45 | Bismuth Iodoform Parrafin | 22 | | |
| 22 | Amlodipine | 4,19 | 46 | Bleomycin | 15 | | |
| 23 | Amoxycillin | 2, 12 | 47 | Boric Acid | 22 | | |
| 24 | Amoxycillin + Clavulanic acid | 12 | 48 | Brimondidine | 27 | | |
| 25 | Amphotericin B | 14 | 49 | Bromohexine Hydrochloride | 8, 28 | | |
| 26 | Ampicillin | 2, 12 | 50 | Bromocriptine | 16 | | |
| 27 | Anti diptheritic Serum | 25 | 51 | Budesonide | 8, 29 | | |
| 28 | Anti Rabies vaccine | | 52 | Bupivacaine Hydrochloride | 9 | | |
| | (Chick Embryo/vero cell/human diploid Cells) | 25 | 53 | Buprenorphine | 10 | | |
| 29 | Anti Rh (D) Immunoglobulin Po | | 54 | Calamine lotion IP | 4, 20 | | |

| S.No. | Drug Name | Page no. | S.No. | Drug Name | Page no. |
|-------|---|------------|-------|--|---------------|
| 55 | Calcium Carbonate | 8,32 | 86 | Compressed Air | 9 |
| 56 | Calcium Carbonate + Vitamin D3 | 8, 32 | 87 | Conjugated equine oestrogen | 24 |
| 57 | Calcium Gluconate | 32 | 88 | Crystaline Penicillin | 12 |
| 58 | Capecitabine | 16 | 89 | Cyclophosphamide | 15 |
| 59 | Carbamazepine | 2, 11 | 90 | Cyclosporine A | 15 |
| 60 | Carbimazole | 25 | 91 | Cytosyine Arabinoside (Cytarabin | ie) 15 |
| 61 | Carbon Dioxide | 9 | 92 | D.P.T .I.P., Diphtheria, pertussis | |
| 62 | Carboplatin | 16 | | and tetanus toxoids (DPT) vaccin (adsorbed), prepared from diphthe | |
| 63 | Cefixime | 12 | | formal toxoid containing not less 1500 Limes flocculation(Lf), | than |
| 64 | Ceftazidime | 13 | | a suspension of killed | |
| 65 | Ceftriaxone | 13 | | bordetella pertusis & tetanus toxo containing not less than 1000 Lf | oid |
| 66 | Cephalexin | 2, 12 | | and a mineral carrier which is a suspension of hydrated aluminiur | n |
| 67 | Charcoal | 2 | | hydroxide, aluminium phosphate | |
| 68 | Chloramphenicol 7, | 13, 22, 26 | | calcium phosphate in saline solution or other appropriate solu | tion |
| 69 | Chlorhexidine | 5,21 | | isotonic with blood, The label on each vial should include a | |
| 70 | Chloroquine Phosphate | 3,14 | | Vaccine Vial Monitor (VVM) | |
| 71 | Chlorpheniramine Maleate | 1, 11 | | designed to meet the heat stability curve of the vaccine | |
| 72 | Chlorpromazine | 28 | | supplied. | 6, 25 |
| 73 | Choline Salicylate soln+ Benzalkonium chloride soln + Lignocaine HCL IP | 5, 19 | 93 | D.T. I.P (adsorbed)- sterile solution prepared by mixing purified dipht formal toxoid containing not less 1500 Limes flocculationis (Lf) and | heria than |
| 74 | Cinnarizine | 1, 11 | | purified tetanus formal toxoid | |
| 75 | Ciprofloxacin 2, 7 | 7,13,22,26 | | containing not less than 1000 Lim flocculation, is with a suspension | |
| 76 | Cisplatin | 15 | | mineral carrier in a saline solution appropriate solution isotonic with | |
| 77 | Clobetasol propionate | 20 | | blood.,The label on each vial sho | uld |
| 78 | Clofazimine | 3, 13 | | include a Vaccine Vial Monitor (VVM) designed to meet the heat | |
| 79 | Clomiphene citrate | 24 | | stability curve of the vaccine supplied | 6, 25 |
| 80 | Clomipramine hydrochloride | 28 | 94 | Dacarbazine | 0, 23 |
| 81 | Clonazepam | 12 | 95 | Danazol | 24 |
| 82 | Clonidine | 19 | 96 | Dapsone | 3,13 |
| 83 | Clotrimazole | 4,5,20,22 | 97 | Dapsone | 15 |
| 84 | Cloxacillin | 2,12 | 98 | Deferiprone | 11 |
| 85 | Coal tar | 20 | 90 | Deteriprofile | 11 |

| S.No. | Drug Name | Page no. | S.No. | Drug Name F | Page no. |
|-------|--|-------------|-------|--|----------|
| 99 | Deseferroxamine | 11 | 130 | Enalapril | 4, 19 |
| 100 | Dexamethasone | 26 | 131 | Enoxaparin | 17 |
| 101 | Dexamethasone + Gentamycin | 26 | 132 | Entacavir | 14 |
| 102 | Dexamethasone + Ofloxacin | 26 | 133 | Enteral nutrition | 30 |
| 103 | Dexamethasone Sodium Phospha | ate 1, 11 | 134 | Erythromycin (as Stearate) | 2, 13 |
| 104 | Dextran 40 | 18 | 135 | Erythropoetin | 17 |
| 105 | Dextromethorphan | 8, 28 | 136 | Ethacridine Lactate | 27 |
| 106 | Dextrose | 8, 29 | 137 | Ethambutol | 3,13 |
| 107 | Dextrose with multiple electrolyte | s 29 | 138 | Ethinyl Oestradiol | 24 |
| 108 | Dextrose with Saline | 29 | 139 | Ethinyl Oestradiol valerate | 24 |
| 109 | Diazepam | 7,10 | 140 | Ethinyl Oestradiol + | 0.04 |
| 110 | Diclofenac Sodium | 1, 10 | | Levonorgestrel | 6,24 |
| 111 | Dicyclomine | 6, 23 | 141 | Ethinyl Oestradiol + Levonorgestrel (extended) | 24 |
| 112 | Dicyclomine+Activated Dimethicone/ Simethicone | 6, 23 | 142 | Ethyl alcohol (70-80%), Denatured | 5,21 |
| 113 | Diethylcarbamazine | 0 10 | 143 | Etophylline+ Theophylline | 8, 28,29 |
| 114 | dihydrogen citrate | 2, 12 | 144 | Etoposide | 15 |
| 115 | Digoxin Dihydroergotamine | 4, 19 10 | 145 | Eusol (Chlorinated lime+ Boric ac | id) 21 |
| 116 | Diloxanide Furoate | 3, 14 | 146 | Factor IX Complex | |
| 117 | Diltiazem | 19 | | (Coagulation Factors II, VII, IX, X) | |
| 117 | Dinoprostone | 27 | 147 | Factor VIII Concentrate | 18 |
| 119 | • | | 148 | Fat/lipid emulsion for Infusion | 31 |
| | Diphenhydramine Distilled water | 28 | 149 | Fenofibrate | 19 |
| 120 | | 30 | 150 | Fentanyl | 9 |
| 121 | Dobutamine | 19 | 151 | Ferrous fumarate | 3,17 |
| 122 | Domperidone | 5, 22 | 152 | Ferrous Sulphate | 3, 17 |
| 123 | Donepezil | 28 | 153 | Fligrastim Granisetron | 16 |
| 124 | Dopamine | 19 | 154 | Fluconazole | 3, 14 |
| 125 | Dorzolamide | 27 | 155 | Fluoxetine | 28 |
| 126 | Doxorubicin | 15 | 156 | Fluphenazine Decanoate | 28 |
| 127 | Doxycycline | 2, 13 | 157 | flurbiprofen | 7, 26 |
| 128 | D-Penicillamine | 11 | 158 | Fluroscein Sodium | 27 |
| 129 | Efavirenz | 15 | 159 | Folic Acid | 3, 17 |

| S.No. | Drug Name | Page no. | S.No. | Drug Name | Page no. |
|-------|---|-------------|-------|--|----------|
| 160 | Formaldehyde | 21 | 185 | Homatropine hydrobromide | 27 |
| 161 | Framycetin | 4,20 | 186 | Human Normal Immunoglobulin (IV-IG) | 25 |
| 162 | Frusemide | 5, 21 | 187 | Human Normal Serum Albumin | 18 |
| 163 | Gabapentine | 12 | | | |
| 164 | Gadoteric acid/ gadobenic acid/ | 1 | 188 | Hyaluronidase | 27 |
| | gadodiamide/ gadopentetate dimeglumine | 21 | 189 | Hydrochlorothiazide | 5, 21 |
| 165 | GCSF | 16 | 190 | Hydrocortisone Sodium Succinate | |
| 166 | Gemcitabine | 16 | 191 | Hydrogen Peroxide | 5, 21 |
| 167 | Gentamicin 5 | 5,13, 22,26 | 192 | Hydroxy Chloroquine Phosphate | 10 |
| 168 | Gentamicin + Betamethasone | 5, 22 | 193 | Hydroxy Progesterone acetate (d | epot) 24 |
| 169 | Gentian violet | 5, 21 | 194 | Hydroxy Propyl Methyl Cellulose | 27 |
| 170 | Glimepiride | 6, 24 | 195 | Hyoscine Butyl Bromide | 6, 23 |
| 171 | Glutaraldehyde Activated withou | | 196 | Ibuprofen | 1, 10 |
| 17.1 | Foaming to remain Alkaline | | 197 | Icthymol | 22 |
| | for 2 weeks | 21 | 198 | Ifosfamide with mesna | 16 |
| 172 | Glycerine enema | 23 | 199 | Imatinib | 16 |
| 173 | Glycerol | 21 | 200 | Imipramine | 7, 28 |
| 174 | Glyceryl Trinitrate | 4,18 | 201 | Indinavir (IDV) | 15 |
| 175 | Glycine | 30 | 202 | Indomethacin | 10 |
| 176 | Glycopyrrolate | 10 | 203 | Insulin Glargine(Human) | 24 |
| 177 | Granisetron | 15 | 204 | Insulin lispro / Apart/ glulisine | 24 |
| 178 | Griseofulvin Ultra-micronised | 3, 14 | 205 | Insulin NPH (Human) | 24 |
| 179 | Haloperidol | 28 | 206 | Insulin Premixed (Human) | 24 |
| 180 | Halothane | 9 | 207 | Insulin Soluble (Human) | 24 |
| 181 | Heparin sodium | 18 | 208 | Intraperitoneal Dialysis | |
| 182 | Hepatitis B Immunoglobulin | 25 | | Concentrate | 28 |
| 183 | Hepatitis- B Vaccine (DNA recombinant genetically | | 209 | lohexol/ lopamidol / lomeprol/ loversol/lodixanol/ lobitridol | 21 |
| | engineered non-infectious vacc The label on each vial should | ine), | 210 | Ipratropium bromide | 29 |
| | include a Vaccine Vial Monitor | | 211 | Iron Dextran | 17 |
| | (VVM),The Vaccine Vial Monitor (VVM) shall be as per WHO | r | 212 | Iron Folic Acid | 3, 17 |
| | Specifications | 7,25 | 213 | iron Sucrose | 17 |
| 184 | Heta Starch (Hydroxy ethyl star | ch) 18 | 214 | Isoflurane | 9 |

| S.No. | Drug Name | Page no. | S.No. | Drug Name | Page no. |
|-------|--|-------------|-------|---|-------------------|
| 215 | Isoniazid | 3, 13 | 244 | Measles I.P. Freeze dried vacc | |
| 216 | Isoniazid + B6 | 3, 13 | | with sterile diluent in correspon quantity. The diluent does not | aing |
| 217 | Isosorbide dinitrate | 4, 18 | | contain any added antimicrobia preservative. | ıl 6, 25 |
| 218 | Isosorbide mononitrate | 4, 18 | 245 | Mebendazole | 2, 12 |
| 219 | Isoxsuprine | 27 | 246 | Medroxy Progesterone Acetate | |
| 220 | Ispaghula Husk | 6, 23 | 247 | Mefloquine Phosphate | 14 |
| 221 | Ivermectin | 12 | 248 | Melphalan | 16 |
| 222 | Ketamine Hydrochloride | 9 | 249 | Mercaptopurine | 16 |
| 223 | L- asparaginase | 15 | 250 | Meropenem | 13 |
| 224 | labetolol | 19 | 251 | Metformin hydrochloride | 6,24 |
| 225 | Lactulose | 23 | 252 | Methocarbamol | 7,25 |
| 226 | Lamivudine (3TC.) | 14 | 253 | Methotrexate | 15 |
| 227 | Lamotrigine | 12 | 254 | Methyldopa | 4,19 |
| 228 | Letrozole | 16 | 255 | Methylergometrine Maleate | 7, 27 |
| 229 | Leucovorin (calcium) | 16,15 | 256 | Methylithonium chloride | 7, 27 |
| 230 | Levamisole | 20 | 200 | (Methylene Blue) | 11 |
| 231 | Levocetirizine | 1, 11 | 257 | Methylprednisolone | 23 |
| 232 | Levodopa + Carbidopa | 16 | 258 | Metoclopramide | 5,22 |
| 233 | Levofloxacin | 13 | 259 | Metoprolol | 4, 18 |
| 234 | Levothyroxine | 6, 24 | 260 | Metronidazole | 3, 5, 14,19 |
| 235 | Lignocaine | | 261 | Miconazole Nitrate | 4, 20 |
| | | 1, 9,10, 19 | 262 | Midazolam | 10 |
| 236 | liquid paraffin | 20 | 263 | Mifepristone | 27 |
| 237 | Lithium carbonate | 28 | 264 | Misoprostol | 27 |
| 238 | Lorazepam | . 28 | 265 | Mixed TPN (peripheral) | 31 |
| 239 | Lubricating Eye Drops (Polyviny alcohol 1.4% + Povidone 0.6 % chlorbutanol 0.5%) | | 266 | MMR (Live Vaccine) USP Meas Mumps and Rubella Vaccine (L freeze-dried Freeze-dried vacc | ive) is a |
| 240 | Lugol's lodine soln. | 25 | | sterile diluent in corresponding | quantity. |
| 241 | Magnesium hydroxide + alumini hydroxide + activated dimethico | | | The diluent does not contain ar antimicrobial preservative. | ny added 6, 25 |
| | simethicone | 5,22 | 267 | Morphine Sulphate | 10 |
| 242 | Magnesium sulphate | 11 | 268 | Mosapride citrate dehydrate | 22 |
| 243 | Mannitol | 21 | 269 | Multivitamin | 8, 31,32 |

| S.No. | Drug Name | Page no. | S.No. | Drug Name | Page no. |
|-------|---|----------|-------|---|------------|
| 270 | N Acetyl Cysteine | 11 | 300 | Pheniramine maleate | 1, 11 |
| 271 | Naloxone Hydrochloride | 11 | 301 | Phenobarbitone | 2, 11, 12 |
| 272 | Naltrexone | 28 | 302 | Phenylephrine | 27 |
| 273 | naphazoline HCl + | | 303 | Phenytoin Sodium | 2, 11 |
| | Chlorpheniramine + Zinc Sulfate | | 304 | Pilocarpine | 7, 27 |
| 274 | Natamycin | 26 | 305 | Piperacillin | 13 |
| 275 | Neostigmine | 25 | 306 | Podophyllin | 20 |
| 276 | Nevirapine (NVP) | 15 | 307 | Poliomyelitis I. P. (monovalent | t, |
| 277 | Nifedipine | 27 | | Bivalent, Trivalent), Live attenu stabilised with magnesium | ated |
| 278 | Nitrofurantoin | 13 | | chloride. | 6,7, 25 |
| 279 | Nitrous Oxide | 9 | 308 | Potassium Chloride | 30 |
| 280 | Noradrenaline | 19 | 309 | Potassium Permanganate | 5,21 |
| 281 | Norethisterone | 6, 24 | 310 | Povidone Iodine | 4,19,20,22 |
| 282 | Norfloxacin | 2, 13 | 311 | Pralidoxime Chloride (2-PAM) | 11 |
| 283 | Noscapine | 8, 28 | 312 | Prazocin | 4, 19 |
| 284 | Octreotide | 23 | 313 | Prednisolone | 1, 11 |
| 285 | Olanazapin | 28 | 314 | Primaquine | 14 |
| 286 | Olapatadine | 26 | 315 | Procaine Penicillin G. | 12 |
| 287 | Omeprazole | 5, 22 | 316 | Procarbazine | 16 |
| 288 | Ondansteron | 22 | 317 | Progesterone micronized | 24 |
| 289 | ORS (Low osmolarity: 245 mmo | | 318 | Promethazine hydrochloride | 1,10 |
| | Sod Chloride 2.6 g/ L Trisodium dehydrate 2.9g/L , Pot.Chloride | 1.5g/ | 319 | Proparacain | 27 |
| | L,Glucose anhydrous 13.5g/L) | 6, 23 | 320 | Propofol | 9 |
| 290 | Oxaliplatin | 16 | 321 | Propranolol HCL | 11 |
| 291 | Oxygen | 9 | 322 | Propyl thio uracil | 25 |
| 292 | Oxytocin | 27 | 323 | Protamine Sulphate | 18 |
| 293 | Paclitaxel | 16 | 324 | Pyrazinamide | 3, 13 |
| 294 | Pantoprazole | 22 | 325 | Quinine Sulphate | 14 |
| 295 | Paracetamol | 1, 10 | 326 | Rabies Immunoglobulin | 25 |
| 296 | Pentavalent Vaccine I.P. | 7, 25 | 327 | Ranitidine | 5, 22 |
| 297 | Pentazocin Lactate | 1,10 | 328 | Ribavirin | 14 |
| 298 | Permethrin | 4, 20 | 329 | Rifampicin | 3, 13 |
| 299 | PGF 2 alpha as tromethamine | 27 | | ·· r · · | |

| S.No. | Drug Name | Page no. | S.No. | Drug Name | Page no. |
|-------|--|---------------|-------|--|-------------|
| 330 | Ringer Lactate | 30 | | opalescenceValidity period:36 | 05 |
| 331 | Risperidone | 28 | 050 | monthsStorage:2-8 degree | 25 |
| 332 | Ritonavir | 15 | 359 | Tamoxifen | 15 |
| 333 | rocuronium | 25 | 360 | Tannic Acid | 5, 19 |
| 334 | Salbutamol | 8, 28,29 | 361 | Teicoplanin | 13 |
| 335 | salicylic acid | 20 | 362 | Telmisartan | 4, 19 |
| 336 | Sevoflurane | 9 | 363 | Temozolamide | 16 |
| 337 | silver nitrate | 22 | 364 | Tenofovir | 14 |
| 338 | Silver sulfadiazine | 4, 20 | 365 | Tetanus Toxoid (adsorbed) ste suspension prepared from teta | |
| 339 | sitagliptin/ vildagliptin/ saxagli | ptin 24 | | toxoid containing not less than Limes flocculationis (Lf) adsorb | |
| 340 | Sodium Bicarbonate | 30 | | mineral carrier in saline solution | n |
| 341 | Sodium Chloride/ Normal Saline 5 | , 8, 22,27,29 | | or other appropriate solution is blood. The potency of tetanus shall be at least 60 IU (determi | vaccine |
| 342 | Sodium Diatrizoate and Meglumine Diatrizoate | 21 | | mice) or 40 IU (determined in guinea pig) per single human d | lose. 7, 25 |
| 343 | Sodium Nitroprusside | 19 | 366 | Timolol | 7, 27 |
| 344 | Sodium Stibogluconate | 12 | 367 | Tincture Benzoin Co. | 5, 21 |
| 345 | Sodium thiopentone | 9 | 368 | Tinidazole | 3, 14 |
| 346 | Sodium Valproate | 2,11 | 369 | Tobramycin | 26 |
| 347 | Spironolactone | 5,21 | 370 | Tramadol | 1,10 |
| 348 | Stavudine | 15 | 371 | Tranexamic acid | 4,17,18 |
| 349 | Streptokinase | 18 | 372 | Triamcinolone | 20 |
| 350 | Streptomycin | 3, 13 | 373 | Triclofos sodium | 10 |
| 351 | Succinyl choline | 25 | 374 | Trifluoperazine | 28 |
| 352 | Sulfacetamide | 7,26 | 375 | Trihexyphenidyl | 16 |
| 353 | Sulfamethoxazole + Trimetho | prim 2, 13 | 376 | Trimethyl Psoralen | 20 |
| 354 | Sulfasalazine | 10 | 377 | Trimethoprim | 13 |
| 355 | Sulphadoxine+ Pyrimethamin | e 3, 14 | 378 | Tropicamide | 27 |
| 356 | Sumatriptan | 10 | 379 | Tropicamide + Phenylephrine | 27 |
| 357 | Surfactant Solution for | | 380 | Trypan Blue | 27 |
| | intratracheal instilation | 29 | 381 | Turpentine oil | 22 |
| 358 | T.I.G-Human. (sterile solution globulin),Clear colourless or light yellow liquid with | of | 382 | Typhoid Vaccine (Vi antigen),Capsular Polysacc of salmonella typhi Ty2 25mcg | |

| S.No. | Drug Name F | age no. | S.No. | Drug Name | Page no. |
|-------|----------------------------------|----------|-------|------------------------------|----------|
| | phenol IP as preservative0.25%w/ | /v 7, 25 | 394 | Vitamin B3 (nicotinamide) | 8,31 |
| 383 | Urodeoxy cholic acid | 23 | 395 | Vitamin B6 (Pyridoxine) | 8,31 |
| 384 | Vancomycin as hydrochloride | 13 | 396 | Vitamin C | 8,32 |
| 385 | Vecuronium | 25 | 397 | Vitamin D3 (cholecalciferol) | 8,31,32 |
| 386 | Verapamil | 19 | 398 | Vitamin K | 18,31 |
| 387 | Vinblastine | 16 | 399 | Warfarin | 18 |
| 388 | Vincristine | 16 | 400 | Water for Injection | 30 |
| 389 | Vinorelbine | 16 | 401 | Wax dissolvent | 5, 22 |
| 390 | Vitamin A (Retinol) | 8,31 | 402 | Xylometazoline | 5,21 |
| 391 | Vitamin B1 (Thiamin pyrophospha | te) 8,31 | 403 | Zidovudine (ZDVor AZT) | 14 |
| 392 | Vitamin B12(Cobalamin) | 8,32 | 404 | Zinc sulfate | 8,32 |
| 393 | Vitamin B2 (riboflavin) | 8,31 | 405 | Zoledronic Acid | 16 |
| | | | 406 | Zolpidem | 28 |





DIRECTORATE OF HEALTH SERVICES

Govt. of NCT of Delhi F-17, Karkardooma, Delhi-110032 www.health.delhigovt.nic.in email: dirdhs@nic.in